ID   FINC_HUMAN              Reviewed;        2477 AA.
AC   P02751; B7ZLF0; E9PE77; E9PG29; O95609; O95610; Q14312; Q14325; Q14326;
AC   Q17RV7; Q53S27; Q564H7; Q585T2; Q59EH1; Q60FE4; Q68DP8; Q68DP9; Q68DT4;
AC   Q6LDP6; Q6MZS0; Q6MZU5; Q6N025; Q6N0A6; Q7Z391; Q86T27; Q8IVI8; Q96KP7;
AC   Q96KP8; Q96KP9; Q9H1B8; Q9HAP3; Q9UMK2;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   16-OCT-2019, sequence version 5.
DT   18-JUN-2025, entry version 287.
DE   RecName: Full=Fibronectin {ECO:0000305};
DE            Short=FN;
DE   AltName: Full=Cold-insoluble globulin;
DE            Short=CIG;
DE   Contains:
DE     RecName: Full=Anastellin;
DE   Contains:
DE     RecName: Full=Ugl-Y1;
DE   Contains:
DE     RecName: Full=Ugl-Y2;
DE   Contains:
DE     RecName: Full=Ugl-Y3;
DE   Flags: Precursor;
GN   Name=FN1 {ECO:0000312|HGNC:HGNC:3778}; Synonyms=FN;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 16).
RX   PubMed=11737888; DOI=10.1186/bcr325;
RA   Schor S.L., Schor A.M.;
RT   "Phenotypic and genetic alterations in mammary stroma: implications for
RT   tumour progression.";
RL   Breast Cancer Res. 3:373-379(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 16).
RX   PubMed=16322219; DOI=10.1158/0008-5472.can-05-2038;
RA   Kay R.A., Ellis I.R., Jones S.J., Perrier S., Florence M.M., Schor A.M.,
RA   Schor S.L.;
RT   "The expression of migration stimulating factor, a potent oncofetal
RT   cytokine, is uniquely controlled by 3'-untranslated region-dependent
RT   nuclear sequestration of its precursor messenger RNA.";
RL   Cancer Res. 65:10742-10749(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 14), AND VARIANTS PRO-817 AND ILE-2261.
RC   TISSUE=Retinal pigment epithelium;
RX   PubMed=16106752; DOI=10.1093/dnares/12.1.53;
RA   Kato S., Ohtoko K., Ohtake H., Kimura T.;
RT   "Vector-capping: a simple method for preparing a high-quality full-length
RT   cDNA library.";
RL   DNA Res. 12:53-62(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 14), AND VARIANTS LEU-15;
RP   PRO-817 AND ILE-2261.
RC   TISSUE=Aortic endothelium;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3; 7; 8; 9; 10; 13; 14; 15
RP   AND 16), AND VARIANTS LEU-15; PRO-817 AND ILE-2261.
RC   TISSUE=Amygdala, Cervix, Colon endothelium, Endometrial tumor, and
RC   Uterine endothelium;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANTS LEU-15; PRO-817
RP   AND ILE-2261.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 10), AND VARIANTS LEU-15;
RP   PRO-817 AND ILE-2261.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-38.
RC   TISSUE=Mammary cancer;
RX   PubMed=3770189; DOI=10.1016/0014-5793(86)80029-1;
RA   Gutman A., Yamada K.M., Kornblihtt A.R.;
RT   "Human fibronectin is synthesized as a pre-propolypeptide.";
RL   FEBS Lett. 207:145-148(1986).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-49, AND VARIANT LEU-15.
RX   PubMed=3031656; DOI=10.1073/pnas.84.7.1876;
RA   Dean D.C., Bowlus C.L., Bourgeois S.;
RT   "Cloning and analysis of the promotor region of the human fibronectin
RT   gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:1876-1880(1987).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 28-2386 (ISOFORM 3), AND VARIANTS PRO-817 AND
RP   ILE-2261.
RC   TISSUE=Fibroblast;
RX   PubMed=2992939; DOI=10.1002/j.1460-2075.1985.tb03847.x;
RA   Kornblihtt A.R., Umezawa K., Vibe-Pedersen K., Baralle F.E.;
RT   "Primary structure of human fibronectin: differential splicing may generate
RT   at least 10 polypeptides from a single gene.";
RL   EMBO J. 4:1755-1759(1985).
RN   [12]
RP   PROTEIN SEQUENCE OF 32-290, CLEAVAGE OF INITIATOR METHIONINE, AND
RP   PYROGLUTAMATE FORMATION AT GLN-32.
RC   TISSUE=Plasma;
RX   PubMed=6630202; DOI=10.1016/s0021-9258(17)44228-1;
RA   Garcia-Pardo A., Pearlstein E., Frangione B.;
RT   "Primary structure of human plasma fibronectin. The 29,000-dalton NH2-
RT   terminal domain.";
RL   J. Biol. Chem. 258:12670-12674(1983).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 103-481 (ISOFORMS
RP   1/3/4/5/6/7/8/9/10/11/12/13/14/15), NUCLEOTIDE SEQUENCE [MRNA] OF 1116-1422
RP   (ISOFORMS 1/3/4/5/6/8/9/10/14), NUCLEOTIDE SEQUENCE [MRNA] OF 1238-2160
RP   (ISOFORMS 9 AND 12), NUCLEOTIDE SEQUENCE [MRNA] OF 1540-1916 (ISOFORMS
RP   8/9/10/13/14), NUCLEOTIDE SEQUENCE [MRNA] OF 2010-2252 (ISOFORMS 3/7/14),
RP   AND NUCLEOTIDE SEQUENCE [MRNA] OF 2319-2477 (ISOFORMS
RP   1/3/6/7/8/9/10/11/12/13/14/15).
RC   TISSUE=Peripheral blood T-cell, and Umbilical vein endothelial cell;
RA   Godfrey H.P., Ebrahim A.A.;
RL   Submitted (DEC-1995) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   PROTEIN SEQUENCE OF 291-302, AND BINDING TO M.BOVIS ANTIGEN 85B (FBPB)
RP   (MICROBIAL INFECTION).
RX   PubMed=8406884; DOI=10.1128/iai.61.11.4828-4834.1993;
RA   Peake P., Gooley A., Britton W.J.;
RT   "Mechanism of interaction of the 85B secreted protein of Mycobacterium
RT   bovis with fibronectin.";
RL   Infect. Immun. 61:4828-4834(1993).
RN   [15]
RP   PROTEIN SEQUENCE OF 309-608, FUNCTION, AND COLLAGEN-BINDING.
RX   PubMed=3024962; DOI=10.1002/j.1460-2075.1986.tb04575.x;
RA   Owens R.J., Baralle F.E.;
RT   "Mapping the collagen-binding site of human fibronectin by expression in
RT   Escherichia coli.";
RL   EMBO J. 5:2825-2830(1986).
RN   [16]
RP   PROTEIN SEQUENCE OF 616-705, AND FUNCTION.
RX   PubMed=3900070; DOI=10.1016/s0021-9258(17)38997-4;
RA   Calaycay J., Pande H., Lee T., Borsi L., Siri A., Shively J.E., Zardi L.;
RT   "Primary structure of a DNA- and heparin-binding domain (Domain III) in
RT   human plasma fibronectin.";
RL   J. Biol. Chem. 260:12136-12141(1985).
RN   [17]
RP   PROTEIN SEQUENCE OF 723-911, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE,
RP   GLYCOSYLATION AT ASN-877, AND VARIANT PRO-817.
RC   TISSUE=Urine;
RX   PubMed=17614963; DOI=10.1111/j.1742-4658.2007.05926.x;
RA   Iida R., Yasuda T., Kishi K.;
RT   "Identification of novel fibronectin fragments detected specifically in
RT   juvenile urine.";
RL   FEBS J. 274:3939-3947(2007).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 973-2386 (ISOFORM 3), AND VARIANT ILE-2261.
RX   PubMed=6462919; DOI=10.1093/nar/12.14.5853;
RA   Kornblihtt A.R., Vibe-Pedersen K., Baralle F.E.;
RT   "Human fibronectin: cell specific alternative mRNA splicing generates
RT   polypeptide chains differing in the number of internal repeats.";
RL   Nucleic Acids Res. 12:5853-5868(1984).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1232-1378, AND NUCLEOTIDE SEQUENCE
RP   [GENOMIC DNA] OF 1685-1873.
RX   PubMed=3375063; DOI=10.1093/nar/16.8.3545;
RA   Paolella G., Henchcliffe C., Sebastio G., Baralle F.E.;
RT   "Sequence analysis and in vivo expression show that alternative splicing of
RT   ED-B and ED-A regions of the human fibronectin gene are independent
RT   events.";
RL   Nucleic Acids Res. 16:3545-3557(1988).
RN   [20]
RP   PROTEIN SEQUENCE OF 1342-1349 AND 1352-1360 (ISOFORMS 7/11/13/15).
RX   PubMed=2822387; DOI=10.1002/j.1460-2075.1987.tb02509.x;
RA   Zardi L., Carnemolla B., Siri A., Petersen T.E., Paolella G., Sebastio G.,
RA   Baralle F.E.;
RT   "Transformed human cells produce a new fibronectin isoform by preferential
RT   alternative splicing of a previously unobserved exon.";
RL   EMBO J. 6:2337-2342(1987).
RN   [21]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1257-1365.
RX   PubMed=3478690; DOI=10.1073/pnas.84.20.7179;
RA   Gutman A., Kornblihtt A.R.;
RT   "Identification of a third region of cell-specific alternative splicing in
RT   human fibronectin mRNA.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:7179-7182(1987).
RN   [22]
RP   PROTEIN SEQUENCE OF 1532-1639.
RX   PubMed=7050098; DOI=10.1016/s0021-9258(18)34113-9;
RA   Pierschbacher M.D., Ruoslahti E., Sundelin J., Lind P., Peterson P.A.;
RT   "The cell attachment domain of fibronectin. Determination of the primary
RT   structure.";
RL   J. Biol. Chem. 257:9593-9597(1982).
RN   [23]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1539-1631.
RX   PubMed=6688418; DOI=10.1016/s0021-9258(17)44437-1;
RA   Oldberg A., Linney E., Ruoslahti E.;
RT   "Molecular cloning and nucleotide sequence of a cDNA clone coding for the
RT   cell attachment domain in human fibronectin.";
RL   J. Biol. Chem. 258:10193-10196(1983).
RN   [24]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1539-1631.
RX   PubMed=3003095; DOI=10.1016/s0021-9258(17)35904-5;
RA   Oldberg A., Ruoslahti E.;
RT   "Evolution of the fibronectin gene. Exon structure of cell attachment
RT   domain.";
RL   J. Biol. Chem. 261:2113-2116(1986).
RN   [25]
RP   PROTEIN SEQUENCE OF 1680-2149 (ISOFORMS 8/14), AND FUNCTION.
RX   PubMed=3593230; DOI=10.1042/bj2410923;
RA   Garcia-Pardo A., Rostagno A., Frangione B.;
RT   "Primary structure of human plasma fibronectin. Characterization of a 38
RT   kDa domain containing the C-terminal heparin-binding site (Hep III site)
RT   and a region of molecular heterogeneity.";
RL   Biochem. J. 241:923-928(1987).
RN   [26]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1685-2477 (ISOFORMS 1/11/15), AND VARIANT
RP   ILE-2261.
RX   PubMed=2992573; DOI=10.1021/bi00332a016;
RA   Bernard M.P., Kolbe M., Weil D., Chu M.-L.;
RT   "Human cellular fibronectin: comparison of the carboxyl-terminal portion
RT   with rat identifies primary structural domains separated by hypervariable
RT   regions.";
RL   Biochemistry 24:2698-2704(1985).
RN   [27]
RP   PROTEIN SEQUENCE OF 1705-1719; 1821-1839; 1847-1850; 1894-1902; 1951-2014;
RP   2021-2036; 2042-2063 AND 2073-2080 (ISOFORMS
RP   1/3/4/5/6/7/8/9/10/11/12/13/14/15/17), PROTEIN SEQUENCE OF 2082-2094
RP   (ISOFORMS 1/3/7/8/11/14/15), PROTEIN SEQUENCE OF 2111-2129 (ISOFORMS
RP   1/3/7/8/9/11/12/14/15/17), PROTEIN SEQUENCE OF 2151-2161 (ISOFORMS
RP   1/3/7/8/9/11/12/14/15), PROTEIN SEQUENCE OF 2162-2222 (ISOFORMS 1/8/11/15),
RP   PROTEIN SEQUENCE OF 2241-2271 (ISOFORMS 1/3/5/7/8/9/10/11/12/13/14/15/17),
RP   PROTEIN SEQUENCE OF 2276-2296 (ISOFORMS 1/3/7/8/9/10/11/12/13/14/15/17),
RP   PROTEIN SEQUENCE OF 2322-2333 (ISOFORMS 1/3/6/7/8/9/10/11/12/13/14/15/17),
RP   VARIANT ILE-2261, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Plasma;
RX   PubMed=2012601; DOI=10.1042/bj2740731;
RA   Tressel T., McCarthy J.B., Calaycay J., Lee T.D., Legesse K., Shively J.E.,
RA   Pande H.;
RT   "Human plasma fibronectin. Demonstration of structural differences between
RT   the A- and B-chains in the III CS region.";
RL   Biochem. J. 274:731-738(1991).
RN   [28]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1632-1901 (ISOFORMS 1/3/6/7/11/15/17), AND
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1715-1818 (ISOFORMS 8/9/10/12/13/14).
RX   PubMed=6200322; DOI=10.1002/j.1460-2075.1984.tb01787.x;
RA   Kornblihtt A.R., Vibe-Pedersen K., Baralle F.E.;
RT   "Human fibronectin: molecular cloning evidence for two mRNA species
RT   differing by an internal segment coding for a structural domain.";
RL   EMBO J. 3:221-226(1984).
RN   [29]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1713-2218 (ISOFORMS 9/12).
RX   PubMed=3021206; DOI=10.1021/bi00365a032;
RA   Sekiguchi K., Klos A.M., Kurachi K., Yoshitake S., Hakomori S.;
RT   "Human liver fibronectin complementary DNAs: identification of two
RT   different messenger RNAs possibly encoding the alpha and beta subunits of
RT   plasma fibronectin.";
RL   Biochemistry 25:4936-4941(1986).
RN   [30]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1879-2477 (ISOFORM 4), NUCLEOTIDE SEQUENCE
RP   [MRNA] OF 1879-2400 (ISOFORMS 5 AND 6), AND VARIANT ILE-2261.
RC   TISSUE=Cartilage;
RX   PubMed=12127832; DOI=10.1053/joca.2002.0792;
RA   Parker A.E., Boutell J., Carr A., Maciewicz R.A.;
RT   "Novel cartilage-specific splice variants of fibronectin.";
RL   Osteoarthritis Cartilage 10:528-534(2002).
RN   [31]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2039-2157 (ISOFORMS 1/3/7/8/11/14/15).
RX   PubMed=2989004; DOI=10.1016/0014-5793(85)81333-8;
RA   Umezawa K., Kornblihtt A.R., Baralle F.E.;
RT   "Isolation and characterization of cDNA clones for human liver
RT   fibronectin.";
RL   FEBS Lett. 186:31-34(1985).
RN   [32]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 2083-2238.
RX   PubMed=3770201; DOI=10.1016/0014-5793(86)81506-x;
RA   Vibe-Pedersen K., Magnusson S., Baralle F.E.;
RT   "Donor and acceptor splice signals within an exon of the human fibronectin
RT   gene: a new type of differential splicing.";
RL   FEBS Lett. 207:287-291(1986).
RN   [33]
RP   PROTEIN SEQUENCE OF 2162-2447 (ISOFORMS 3/7/9/12/14/17), AND VARIANT
RP   ILE-2261.
RX   PubMed=4019516; DOI=10.1016/s0021-9258(17)39250-5;
RA   Garcia-Pardo A., Pearlstein E., Frangione B.;
RT   "Primary structure of human plasma fibronectin. Characterization of a
RT   31,000-dalton fragment from the COOH-terminal region containing a free
RT   sulfhydryl group and a fibrin-binding site.";
RL   J. Biol. Chem. 260:10320-10325(1985).
RN   [34]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2382-2477 (ISOFORMS
RP   1/3/5/6/7/8/9/10/11/12/13/14/15/17).
RC   TISSUE=Mammary carcinoma;
RX   PubMed=6304699; DOI=10.1073/pnas.80.11.3218;
RA   Kornblihtt A.R., Vibe-Pedersen K., Baralle F.E.;
RT   "Isolation and characterization of cDNA clones for human and bovine
RT   fibronectins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 80:3218-3222(1983).
RN   [35]
RP   SULFATION.
RX   PubMed=2414772; DOI=10.1073/pnas.82.21.7160;
RA   Liu M.C., Yu S., Sy J., Redman C.M., Lipmann F.;
RT   "Tyrosine sulfation of proteins from the human hepatoma cell line HepG2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:7160-7164(1985).
RN   [36]
RP   IDENTIFICATION OF UGL-Y1, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND
RP   GLYCOSYLATION.
RX   PubMed=3584091; DOI=10.1093/oxfordjournals.jbchem.a121920;
RA   Iida R., Yasuda T., Kishi K.;
RT   "Purification of a young age-related glycoprotein (Ugl-Y) from normal human
RT   urine.";
RL   J. Biochem. 101:357-363(1987).
RN   [37]
RP   INTERACTION WITH FBLN1.
RX   PubMed=1400330; DOI=10.1016/s0021-9258(19)88674-x;
RA   Balbona K., Tran H., Godyna S., Ingham K.C., Strickland D.K.,
RA   Argraves W.S.;
RT   "Fibulin binds to itself and to the carboxyl-terminal heparin-binding
RT   region of fibronectin.";
RL   J. Biol. Chem. 267:20120-20125(1992).
RN   [38]
RP   FUNCTION, AND CHARACTERIZATION OF FIBRIN-BINDING SITE 1.
RX   PubMed=7989369; DOI=10.1016/s0021-9258(18)31786-1;
RA   Rostagno A., Williams M.J., Baron M., Campbell I.D., Gold L.I.;
RT   "Further characterization of the NH2-terminal fibrin-binding site on
RT   fibronectin.";
RL   J. Biol. Chem. 269:31938-31945(1994).
RN   [39]
RP   SUBUNIT, AND FUNCTION (ANASTELLIN).
RX   PubMed=8114919; DOI=10.1038/367193a0;
RA   Morla A., Zhang Z., Ruoslahti E.;
RT   "Superfibronectin is a functionally distinct form of fibronectin.";
RL   Nature 367:193-196(1994).
RN   [40]
RP   INTERACTION WITH LGALS3BP.
RX   PubMed=9501082; DOI=10.1093/emboj/17.6.1606;
RA   Sasaki T., Brakebusch C., Engel J., Timpl R.;
RT   "Mac-2 binding protein is a cell-adhesive protein of the extracellular
RT   matrix which self-assembles into ring-like structures and binds beta1
RT   integrins, collagens and fibronectin.";
RL   EMBO J. 17:1606-1613(1998).
RN   [41]
RP   INTERACTION WITH S.PNEUMONIAE FIBRONECTIN-BINDING PROTEIN (MICROBIAL
RP   INFECTION).
RX   PubMed=11580843; DOI=10.1046/j.1365-2958.2001.02610.x;
RA   Holmes A.R., McNab R., Millsap K.W., Rohde M., Hammerschmidt S.,
RA   Mawdsley J.L., Jenkinson H.F.;
RT   "The pavA gene of Streptococcus pneumoniae encodes a fibronectin-binding
RT   protein that is essential for virulence.";
RL   Mol. Microbiol. 41:1395-1408(2001).
RN   [42]
RP   FUNCTION (ANASTELLIN).
RX   PubMed=11209058; DOI=10.1073/pnas.98.2.620;
RA   Yi M., Ruoslahti E.;
RT   "A fibronectin fragment inhibits tumor growth, angiogenesis, and
RT   metastasis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:620-624(2001).
RN   [43]
RP   INTERACTION WITH COL13A1.
RX   PubMed=11956183; DOI=10.1074/jbc.m107583200;
RA   Tu H., Sasaki T., Snellman A., Gohring W., Pirila P., Timpl R.,
RA   Pihlajaniemi T.;
RT   "The type XIII collagen ectodomain is a 150-nm rod and capable of binding
RT   to fibronectin, nidogen-2, perlecan, and heparin.";
RL   J. Biol. Chem. 277:23092-23099(2002).
RN   [44]
RP   INTERACTION WITH COMP.
RX   PubMed=12225811; DOI=10.1016/s0945-053x(02)00015-x;
RA   Di Cesare P.E., Chen F.S., Moergelin M., Carlson C.S., Leslie M.P.,
RA   Perris R., Fang C.;
RT   "Matrix-matrix interaction of cartilage oligomeric matrix protein and
RT   fibronectin.";
RL   Matrix Biol. 21:461-470(2002).
RN   [45]
RP   INTERACTION WITH MYOC.
RX   PubMed=11773026;
RA   Filla M.S., Liu X., Nguyen T.D., Polansky J.R., Brandt C.R., Kaufman P.L.,
RA   Peters D.M.;
RT   "In vitro localization of TIGR/MYOC in trabecular meshwork extracellular
RT   matrix and binding to fibronectin.";
RL   Invest. Ophthalmol. Vis. Sci. 43:151-161(2002).
RN   [46]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-528.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [47]
RP   FUNCTION (ANASTELLIN).
RX   PubMed=15665290; DOI=10.1158/0008-5472.148.65.1;
RA   Ambesi A., Klein R.M., Pumiglia K.M., McKeown-Longo P.J.;
RT   "Anastellin, a fragment of the first type III repeat of fibronectin,
RT   inhibits extracellular signal-regulated kinase and causes G(1) arrest in
RT   human microvessel endothelial cells.";
RL   Cancer Res. 65:148-156(2005).
RN   [48]
RP   GLYCOSYLATION AT THR-279; ASN-430; ASN-528; ASN-542; ASN-877; ASN-1007;
RP   ASN-1244 AND ASN-2199.
RX   PubMed=16037490; DOI=10.1093/glycob/cwj019;
RA   Tajiri M., Yoshida S., Wada Y.;
RT   "Differential analysis of site-specific glycans on plasma and cellular
RT   fibronectins: application of a hydrophilic affinity method for glycopeptide
RT   enrichment.";
RL   Glycobiology 15:1332-1340(2005).
RN   [49]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-430; ASN-528; ASN-542; ASN-1007
RP   AND ASN-1244.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [50]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2475, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [51]
RP   INTERACTION WITH FST3.
RX   PubMed=16336961; DOI=10.1016/j.yexcr.2005.11.006;
RA   Maguer-Satta V., Forissier S., Bartholin L., Martel S., Jeanpierre S.,
RA   Bachelard E., Rimokh R.;
RT   "A novel role for fibronectin type I domain in the regulation of human
RT   hematopoietic cell adhesiveness through binding to follistatin domains of
RT   FLRG and follistatin.";
RL   Exp. Cell Res. 312:434-442(2006).
RN   [52]
RP   INTERACTION WITH TNFAIP6 AND THBS1.
RX   PubMed=18042364; DOI=10.1016/j.matbio.2007.10.003;
RA   Kuznetsova S.A., Mahoney D.J., Martin-Manso G., Ali T., Nentwich H.A.,
RA   Sipes J.M., Zeng B., Vogel T., Day A.J., Roberts D.D.;
RT   "TSG-6 binds via its CUB_C domain to the cell-binding domain of fibronectin
RT   and increases fibronectin matrix assembly.";
RL   Matrix Biol. 27:201-210(2008).
RN   [53]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2475, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by enrichment
RT   and fractionation of phosphopeptides with strong anion exchange
RT   chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [54]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-528 AND ASN-1007.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [55]
RP   GLYCOSYLATION AT ASN-528; ASN-542 AND ASN-1007.
RX   PubMed=19139490; DOI=10.1074/mcp.m800504-mcp200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F., Zheng Z.B.,
RA   Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y., Zhang Y.K., Deng Y.L.,
RA   Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core fucosylated
RT   glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [56]
RP   FUNCTION (ANASTELLIN), AND MUTAGENESIS OF LEU-663 AND TYR-666.
RX   PubMed=19379667; DOI=10.1016/j.matbio.2009.01.003;
RA   You R., Klein R.M., Zheng M., McKeown-Longo P.J.;
RT   "Regulation of p38 MAP kinase by anastellin is independent of anastellin's
RT   effect on matrix fibronectin.";
RL   Matrix Biol. 28:101-109(2009).
RN   [57]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S., Fischer-Posovszky P.,
RA   Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [58]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-2454 AND SER-2475, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [59]
RP   PHOSPHORYLATION AT SER-2475.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [60]
RP   DEVELOPMENTAL STAGE, AND TISSUE SPECIFICITY.
RX   PubMed=29777959; DOI=10.1016/j.actbio.2018.05.023;
RA   Felemban M., Dorgau B., Hunt N.C., Hallam D., Zerti D., Bauer R., Ding Y.,
RA   Collin J., Steel D., Krasnogor N., Al-Aama J., Lindsay S., Mellough C.,
RA   Lako M.;
RT   "Extracellular matrix component expression in human pluripotent stem cell-
RT   derived retinal organoids recapitulates retinogenesis in vivo and reveals
RT   an important role for IMPG1 and CD44 in the development of photoreceptors
RT   and interphotoreceptor matrix.";
RL   Acta Biomater. 74:207-221(2018).
RN   [61]
RP   INTERACTION WITH S.SUIS FIBRONECTIN-BINDING PROTEIN (MICROBIAL INFECTION).
RX   PubMed=27834729; DOI=10.1073/pnas.1608406113;
RA   Musyoki A.M., Shi Z., Xuan C., Lu G., Qi J., Gao F., Zheng B., Zhang Q.,
RA   Li Y., Haywood J., Liu C., Yan J., Shi Y., Gao G.F.;
RT   "Structural and functional analysis of an anchorless fibronectin-binding
RT   protein FBPS from Gram-positive bacterium Streptococcus suis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 113:13869-13874(2016).
RN   [62]
RP   SUBCELLULAR LOCATION, INVOLVEMENT IN SMDCF, VARIANTS SMDCF PHE-87; ARG-123;
RP   TRP-225; ASP-240; GLY-260 AND THR-809 DEL, AND CHARACTERIZATION OF VARIANTS
RP   SMDCF PHE-87; ASP-240 AND GLY-260.
RX   PubMed=29100092; DOI=10.1016/j.ajhg.2017.09.019;
RG   Baylor-Hopkins Center for Mendelian Genomics;
RA   Lee C.S., Fu H., Baratang N., Rousseau J., Kumra H., Sutton V.R.,
RA   Niceta M., Ciolfi A., Yamamoto G., Bertola D., Marcelis C.L.,
RA   Lugtenberg D., Bartuli A., Kim C., Hoover-Fong J., Sobreira N., Pauli R.,
RA   Bacino C., Krakow D., Parboosingh J., Yap P., Kariminejad A.,
RA   McDonald M.T., Aracena M.I., Lausch E., Unger S., Superti-Furga A.,
RA   Lu J.T., Cohn D.H., Tartaglia M., Lee B.H., Reinhardt D.P., Campeau P.M.;
RT   "Mutations in fibronectin cause a subtype of spondylometaphyseal dysplasia
RT   with 'corner fractures'.";
RL   Am. J. Hum. Genet. 101:815-823(2017).
RN   [63]
RP   FUNCTION, AND LILRB4-BINDING REGION.
RX   PubMed=34089617; DOI=10.1093/intimm/dxab028;
RA   Su M.T., Inui M., Wong Y.L., Takahashi M., Sugahara-Tobinai A., Ono K.,
RA   Miyamoto S., Murakami K., Itoh-Nakadai A., Kezuka D., Itoi S., Endo S.,
RA   Hirayasu K., Arase H., Takai T.;
RT   "Blockade of checkpoint ILT3/LILRB4/gp49B binding to fibronectin
RT   ameliorates autoimmune disease in BXSB/Yaa mice.";
RL   Int. Immunol. 33:447-458(2021).
RN   [64]
RP   STRUCTURE BY NMR OF 1538-1631.
RX   PubMed=1311202; DOI=10.1021/bi00122a025;
RA   Baron M., Main A.L., Driscoll P.C., Mardon H.J., Boyd J., Campbell I.D.;
RT   "1H NMR assignment and secondary structure of the cell adhesion type III
RT   module of fibronectin.";
RL   Biochemistry 31:2068-2073(1992).
RN   [65]
RP   STRUCTURE BY NMR OF 1538-1631.
RX   PubMed=1423622; DOI=10.1016/0092-8674(92)90600-h;
RA   Main A.L., Harvey T.S., Baron M., Boyd J., Campbell I.D.;
RT   "The three-dimensional structure of the tenth type III module of
RT   fibronectin: an insight into RGD-mediated interactions.";
RL   Cell 71:671-678(1992).
RN   [66]
RP   STRUCTURE BY NMR OF 183-275, AND DISULFIDE BONDS.
RX   PubMed=8308892; DOI=10.1006/jmbi.1994.1083;
RA   Williams M.J., Phan I., Harvey T.S., Rostagno A., Gold L.I., Campbell I.D.;
RT   "Solution structure of a pair of fibronectin type 1 modules with fibrin
RT   binding activity.";
RL   J. Mol. Biol. 235:1302-1311(1994).
RN   [67]
RP   STRUCTURE BY NMR OF 32-92.
RX   PubMed=7583666; DOI=10.1038/nsb1195-946;
RA   Potts J.R., Phan I., Williams M.J., Campbell I.D.;
RT   "High-resolution structural studies of the factor XIIIa crosslinking site
RT   and the first type 1 module of fibronectin.";
RL   Nat. Struct. Biol. 2:946-950(1995).
RN   [68]
RP   STRUCTURE BY NMR OF 406-464.
RX   PubMed=9514732; DOI=10.1006/jmbi.1997.1528;
RA   Sticht H., Pickford A.R., Potts J.R., Campbell I.D.;
RT   "Solution structure of the glycosylated second type 2 module of
RT   fibronectin.";
RL   J. Mol. Biol. 276:177-187(1998).
RN   [69]
RP   STRUCTURE BY NMR OF EXTRA DOMAIN B FROM ISOFORM 7.
RX   PubMed=10196121; DOI=10.1016/s0969-2126(99)80051-3;
RA   Fattorusso R., Pellecchia M., Viti F., Neri P., Neri D., Wuethrich K.;
RT   "NMR structure of the human oncofoetal fibronectin ED-B domain, a specific
RT   marker for angiogenesis.";
RL   Structure 7:381-390(1999).
RN   [70]
RP   STRUCTURE BY NMR OF 305-405.
RX   PubMed=10647176; DOI=10.1016/s0969-2126(00)88336-7;
RA   Bocquier A.A., Potts J.R., Pickford A.R., Campbell I.D.;
RT   "Solution structure of a pair of modules from the gelatin-binding domain of
RT   fibronectin.";
RL   Structure 7:1451-1460(1999).
RN   [71]
RP   STRUCTURE BY NMR OF 305-464, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-430.
RX   PubMed=11285216; DOI=10.1093/emboj/20.7.1519;
RA   Pickford A.R., Smith S.P., Staunton D., Boyd J., Campbell I.D.;
RT   "The hairpin structure of the (6)F1(1)F2(2)F2 fragment from human
RT   fibronectin enhances gelatin binding.";
RL   EMBO J. 20:1519-1529(2001).
RN   [72]
RP   STRUCTURE BY NMR OF 1722-1815.
RX   PubMed=11775745; DOI=10.1023/a:1012947209393;
RA   Niimi T., Osawa M., Yamaji N., Yasunaga K., Sakashita H., Mase T.,
RA   Tanaka A., Fujita S.;
RT   "NMR structure of human fibronectin EDA.";
RL   J. Biomol. NMR 21:281-284(2001).
RN   [73]
RP   STRUCTURE BY NMR OF 631-705, AND MUTAGENESIS OF TYR-641; ILE-642; LEU-663;
RP   TYR-666; LEU-681; ILE-682; SER-683; ILE-684; GLU-691; VAL-692; ARG-694;
RP   PHE-695; ASP-696 AND PHE-697.
RX   PubMed=12946358; DOI=10.1016/s0022-2836(03)00890-8;
RA   Briknarova K., Aakerman M.E., Hoyt D.W., Ruoslahti E., Ely K.R.;
RT   "Anastellin, an FN3 fragment with fibronectin polymerization activity,
RT   resembles amyloid fibril precursors.";
RL   J. Mol. Biol. 332:205-215(2003).
RN   [74]
RP   STRUCTURE BY NMR OF 48-140 IN COMPLEX WITH A STAPHYLOCOCCUS
RP   FIBRONECTIN-BINDING PROTEIN, SUBUNIT (MICROBIAL INFECTION), AND DISULFIDE
RP   BONDS.
RX   PubMed=12736686; DOI=10.1038/nature01589;
RA   Schwarz-Linek U., Werner J.M., Pickford A.R., Gurusiddappa S., Kim J.H.,
RA   Pilka E.S., Briggs J.A., Gough T.S., Hoeoek M., Campbell I.D., Potts J.R.;
RT   "Pathogenic bacteria attach to human fibronectin through a tandem beta-
RT   zipper.";
RL   Nature 423:177-181(2003).
RN   [75]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1538-1626.
RX   PubMed=8120888; DOI=10.1016/0022-2836(94)90013-2;
RA   Dickinson C.D., Veerapandian B., Dai X.-P., Hamlin R.C., Xuong N.-H.,
RA   Ruoslahti E., Ely K.R.;
RT   "Crystal structure of the tenth type III cell adhesion module of human
RT   fibronectin.";
RL   J. Mol. Biol. 236:1079-1092(1994).
RN   [76]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1173-1540.
RX   PubMed=8548820; DOI=10.1016/s0092-8674(00)81002-8;
RA   Leahy D.J., Aukhil I., Erickson H.P.;
RT   "2.0 A crystal structure of a four-domain segment of human fibronectin
RT   encompassing the RGD loop and synergy region.";
RL   Cell 84:155-164(1996).
RN   [77]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 1812-2082.
RX   PubMed=10075919; DOI=10.1093/emboj/18.6.1468;
RA   Sharma A., Askari J.A., Humphries M.J., Jones E.Y., Stuart D.I.;
RT   "Crystal structure of a heparin- and integrin-binding segment of human
RT   fibronectin.";
RL   EMBO J. 18:1468-1479(1999).
RN   [78]
RP   STRUCTURE BY NMR OF 608-701.
RX   PubMed=14657397; DOI=10.1073/pnas.2334390100;
RA   Gao M., Craig D., Lequin O., Campbell I.D., Vogel V., Schulten K.;
RT   "Structure and functional significance of mechanically unfolded fibronectin
RT   type III1 intermediates.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:14784-14789(2003).
RN   [79]
RP   STRUCTURE BY NMR OF 609-809.
RX   PubMed=17464288; DOI=10.1038/sj.emboj.7601694;
RA   Vakonakis I., Staunton D., Rooney L.M., Campbell I.D.;
RT   "Interdomain association in fibronectin: insight into cryptic sites and
RT   fibrillogenesis.";
RL   EMBO J. 26:2575-2583(2007).
RN   [80]
RP   STRUCTURE BY NMR OF 93-182, X-RAY CRYSTALLOGRAPHY (1.2 ANGSTROMS) OF
RP   93-182, AND DISULFIDE BONDS.
RX   PubMed=17368672; DOI=10.1016/j.jmb.2007.02.061;
RA   Rudino-Pinera E., Ravelli R.B., Sheldrick G.M., Nanao M.H.,
RA   Korostelev V.V., Werner J.M., Schwarz-Linek U., Potts J.R., Garman E.F.;
RT   "The solution and crystal structures of a module pair from the
RT   Staphylococcus aureus-binding site of human fibronectin -- a tale with a
RT   twist.";
RL   J. Mol. Biol. 368:833-844(2007).
RN   [81]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 93-275 IN COMPLEX WITH
RP   STAPHYLOCOCCUS AUREUS FNBA.
RX   PubMed=18713862; DOI=10.1073/pnas.0803556105;
RA   Bingham R.J., Rudino-Pinera E., Meenan N.A.G., Schwarz-Linek U.,
RA   Turkenburg J.P., Hoeoek M., Garman E.F., Potts J.R.;
RT   "Crystal structures of fibronectin-binding sites from Staphylococcus aureus
RT   FnBPA in complex with fibronectin domains.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:12254-12258(2008).
RN   [82]
RP   STRUCTURE BY NMR OF 2330-2390.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the 11th FN1 domain from human fibronectin 1.";
RL   Submitted (MAR-2008) to the PDB data bank.
RN   [83]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 516-608 IN COMPLEX WITH TYPE I
RP   COLLAGEN.
RX   PubMed=19251642; DOI=10.1073/pnas.0812516106;
RA   Erat M.C., Slatter D.A., Lowe E.D., Millard C.J., Farndale R.W.,
RA   Campbell I.D., Vakonakis I.;
RT   "Identification and structural analysis of type I collagen sites in complex
RT   with fibronectin fragments.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:4195-4200(2009).
RN   [84]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASN-940; PRO-1120 AND ASN-2471.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [85]
RP   VARIANTS GFND2 CYS-973; ARG-1925 AND ARG-1974, VARIANTS LEU-15 AND
RP   VAL-2051, AND CHARACTERIZATION OF VARIANTS GFND2 ARG-1925 AND ARG-1974.
RX   PubMed=18268355; DOI=10.1073/pnas.0707730105;
RA   Castelletti F., Donadelli R., Banterla F., Hildebrandt F., Zipfel P.F.,
RA   Bresin E., Otto E., Skerka C., Renieri A., Todeschini M., Caprioli J.,
RA   Caruso R.M., Artuso R., Remuzzi G., Noris M.;
RT   "Mutations in FN1 cause glomerulopathy with fibronectin deposits.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:2538-2543(2008).
RN   [86]
RP   VARIANT [LARGE SCALE ANALYSIS] ILE-2261, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
CC   -!- FUNCTION: Fibronectins bind cell surfaces and various compounds
CC       including collagen, fibrin, heparin, DNA, and actin (PubMed:3024962,
CC       PubMed:3593230, PubMed:3900070, PubMed:7989369). Fibronectins are
CC       involved in cell adhesion, cell motility, opsonization, wound healing,
CC       and maintenance of cell shape (PubMed:3024962, PubMed:3593230,
CC       PubMed:3900070, PubMed:7989369). Involved in osteoblast compaction
CC       through the fibronectin fibrillogenesis cell-mediated matrix assembly
CC       process, essential for osteoblast mineralization (By similarity).
CC       Participates in the regulation of type I collagen deposition by
CC       osteoblasts (By similarity). Acts as a ligand for the LILRB4 receptor,
CC       inhibiting FCGR1A/CD64-mediated monocyte activation (PubMed:34089617).
CC       {ECO:0000250|UniProtKB:P11276, ECO:0000269|PubMed:3024962,
CC       ECO:0000269|PubMed:34089617, ECO:0000269|PubMed:3593230,
CC       ECO:0000269|PubMed:3900070, ECO:0000269|PubMed:7989369}.
CC   -!- FUNCTION: [Anastellin]: Binds fibronectin and induces fibril formation.
CC       This fibronectin polymer, named superfibronectin, exhibits enhanced
CC       adhesive properties. Both anastellin and superfibronectin inhibit tumor
CC       growth, angiogenesis and metastasis. Anastellin activates p38 MAPK and
CC       inhibits lysophospholipid signaling. {ECO:0000269|PubMed:11209058,
CC       ECO:0000269|PubMed:15665290, ECO:0000269|PubMed:19379667,
CC       ECO:0000269|PubMed:8114919}.
CC   -!- FUNCTION: Secreted by contracting muscle, induces liver autophagy, a
CC       degradative pathway for nutrient mobilization and damage removal, and
CC       systemic insulin sensitization via hepatic ITGA5:ITGB1 integrin
CC       receptor signaling. {ECO:0000250|UniProtKB:P11276}.
CC   -!- SUBUNIT: Mostly heterodimers or multimers of alternatively spliced
CC       variants, connected by 2 disulfide bonds near the carboxyl ends; to a
CC       lesser extent homodimers. Interacts with FBLN1, AMBP, TNR, LGALS3BP and
CC       COL13A1. Interacts with FBLN7 (By similarity). Interacts with COMP
CC       (PubMed:12225811). Interacts (via type III repeats 9-14) with TNFAIP6
CC       (via CUB domain); this interaction enhances fibronectin fibril
CC       assembly. TNFAIP6 may act as a bridging molecule between FN1 and THBS1
CC       (PubMed:18042364). Interacts with TNR; the interaction inhibits cell
CC       adhesion and neurite outgrowth (By similarity). Interacts with FST3 and
CC       MYOC. Interacts with SVEP1 (By similarity). {ECO:0000250,
CC       ECO:0000250|UniProtKB:P11276, ECO:0000269|PubMed:11773026,
CC       ECO:0000269|PubMed:11956183, ECO:0000269|PubMed:12225811,
CC       ECO:0000269|PubMed:1400330, ECO:0000269|PubMed:16336961,
CC       ECO:0000269|PubMed:18042364, ECO:0000269|PubMed:18713862,
CC       ECO:0000269|PubMed:19251642, ECO:0000269|PubMed:8114919,
CC       ECO:0000269|PubMed:9501082}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with S.aureus FnbA.
CC       {ECO:0000269|PubMed:12736686}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with M.bovis FbpB via the
CC       collagen-binding region. {ECO:0000269|PubMed:8406884}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with recombinant S.pneumoniae
CC       PavA (rqcH). {ECO:0000269|PubMed:11580843}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with recombinant S.suis FbpS
CC       (rqcH) via fibronectin's N-terminal 30 kDa region.
CC       {ECO:0000269|PubMed:27834729}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with fibronectin-binding
CC       proteins from other Mycobacteria. {ECO:0000269|PubMed:12736686}.
CC   -!- INTERACTION:
CC       P02751; P29279: CCN2; NbExp=5; IntAct=EBI-1220319, EBI-2835375;
CC       P02751; P02452: COL1A1; NbExp=3; IntAct=EBI-1220319, EBI-982999;
CC       P02751; P07585: DCN; NbExp=9; IntAct=EBI-1220319, EBI-9663608;
CC       P02751; P35555: FBN1; NbExp=2; IntAct=EBI-1220319, EBI-2505934;
CC       P02751; P35556: FBN2; NbExp=2; IntAct=EBI-1220319, EBI-6164392;
CC       P02751; O75636: FCN3; NbExp=3; IntAct=EBI-1220319, EBI-11786958;
CC       P02751; P02751: FN1; NbExp=8; IntAct=EBI-1220319, EBI-1220319;
CC       P02751; PRO_0000018520 [P28300]: LOX; NbExp=2; IntAct=EBI-1220319, EBI-20724846;
CC       P02751; Q9Y4K0: LOXL2; NbExp=2; IntAct=EBI-1220319, EBI-7172227;
CC       P02751; P08519: LPA; NbExp=2; IntAct=EBI-1220319, EBI-9232288;
CC       P02751; P11684: SCGB1A1; NbExp=3; IntAct=EBI-1220319, EBI-7797649;
CC       P02751; P05154: SERPINA5; NbExp=3; IntAct=EBI-1220319, EBI-722597;
CC       P02751; Q9NY15: STAB1; NbExp=2; IntAct=EBI-1220319, EBI-2797815;
CC       P02751; P21980: TGM2; NbExp=5; IntAct=EBI-1220319, EBI-727668;
CC       P02751; P07996: THBS1; NbExp=2; IntAct=EBI-1220319, EBI-2530274;
CC       P02751; P98066: TNFAIP6; NbExp=8; IntAct=EBI-1220319, EBI-11700693;
CC       P02751; Q9UMX0: UBQLN1; NbExp=3; IntAct=EBI-1220319, EBI-741480;
CC       P02751; P40337: VHL; NbExp=2; IntAct=EBI-1220319, EBI-301246;
CC       P02751; P14738: fnbA; Xeno; NbExp=23; IntAct=EBI-1220319, EBI-8398157;
CC       P02751; Q53682: fnbB; Xeno; NbExp=19; IntAct=EBI-1220319, EBI-8398005;
CC       P02751; Q53971: fnbB; Xeno; NbExp=4; IntAct=EBI-1220319, EBI-20719966;
CC       P02751; Q93ED6: fne; Xeno; NbExp=8; IntAct=EBI-1220319, EBI-9826140;
CC       P02751; P75358: gapA; Xeno; NbExp=3; IntAct=EBI-1220319, EBI-2259469;
CC       P02751; Q4AAD6: MHJ_0194; Xeno; NbExp=3; IntAct=EBI-1220319, EBI-14034164;
CC       P02751; Q601D1: mhp271; Xeno; NbExp=2; IntAct=EBI-1220319, EBI-13948049;
CC       P02751; P75392: pdhC; Xeno; NbExp=2; IntAct=EBI-1220319, EBI-2259593;
CC       P02751; Q9CKF6: PM1665; Xeno; NbExp=5; IntAct=EBI-1220319, EBI-11164515;
CC       P02751; Q01924: Sfb; Xeno; NbExp=5; IntAct=EBI-1220319, EBI-20729956;
CC       P02751; P23568: tuf; Xeno; NbExp=2; IntAct=EBI-1220319, EBI-2259072;
CC       P02751; PRO_0000045603 [Q99IB8]; Xeno; NbExp=3; IntAct=EBI-1220319, EBI-6927928;
CC       P02751-1; P20908: COL5A1; NbExp=2; IntAct=EBI-22099195, EBI-2464511;
CC       P02751-7; P06241: FYN; NbExp=2; IntAct=EBI-7133890, EBI-515315;
CC       PRO_0000390479; PRO_0000018520 [P28300]: LOX; NbExp=3; IntAct=EBI-15482592, EBI-20724846;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix {ECO:0000305|PubMed:29100092}. Secreted
CC       {ECO:0000250|UniProtKB:P11276}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=17;
CC         Comment=A number of isoforms are produced. The diversity of isoforms
CC         depends on the V region and either of the two extra domains which can
CC         be either included or excluded (partially or completely for the V
CC         region). {ECO:0000305};
CC       Name=15;
CC         IsoId=P02751-15; Sequence=Displayed;
CC       Name=1;
CC         IsoId=P02751-1; Sequence=VSP_060347;
CC       Name=2; Synonyms=MSF-FN70, Migration stimulation factor FN70;
CC         IsoId=P02751-2; Sequence=VSP_060343, VSP_060344, VSP_060345;
CC       Name=3; Synonyms=V89;
CC         IsoId=P02751-3; Sequence=VSP_060347, VSP_060353;
CC       Name=4; Synonyms=Fibronectin III-15X;
CC         IsoId=P02751-4; Sequence=VSP_060347, VSP_060351, VSP_060354,
CC                                  VSP_060355;
CC       Name=5; Synonyms=Fibronectin (V+I-10)-;
CC         IsoId=P02751-5; Sequence=VSP_060347, VSP_060351, VSP_060356;
CC       Name=6; Synonyms=Fibronectin (V+III-15)-;
CC         IsoId=P02751-6; Sequence=VSP_060347, VSP_060350;
CC       Name=7; Synonyms=Fibronectin containing EDB domain;
CC         IsoId=P02751-7; Sequence=VSP_060353;
CC       Name=8; Synonyms=Fibronectin not containing EDA domain;
CC         IsoId=P02751-8; Sequence=VSP_060347, VSP_060349;
CC       Name=9; Synonyms=Fibronectin not containing EDA and EDB domains and
CC       uses V64 variant of IIICS region;
CC         IsoId=P02751-9; Sequence=VSP_060347, VSP_060349, VSP_060352,
CC                                  VSP_060353;
CC       Name=10;
CC         IsoId=P02751-10; Sequence=VSP_060347, VSP_060349, VSP_060351;
CC       Name=11; Synonyms=Fibronectin containing EDB domain, exon x+2;
CC         IsoId=P02751-11; Sequence=VSP_060348;
CC       Name=12;
CC         IsoId=P02751-12; Sequence=VSP_060346, VSP_060349, VSP_060352,
CC                                   VSP_060353;
CC       Name=13;
CC         IsoId=P02751-13; Sequence=VSP_060349, VSP_060351;
CC       Name=14;
CC         IsoId=P02751-14; Sequence=VSP_060347, VSP_060349, VSP_060353;
CC       Name=16; Synonyms=Migration stimulation factor, MSF;
CC         IsoId=P02751-16; Sequence=VSP_060344, VSP_060345;
CC       Name=17;
CC         IsoId=P02751-17; Sequence=VSP_060347, VSP_060352, VSP_060353;
CC   -!- TISSUE SPECIFICITY: Expressed in the inner limiting membrane and around
CC       blood vessels in the retina (at protein level) (PubMed:29777959).
CC       Plasma FN (soluble dimeric form) is secreted by hepatocytes. Cellular
CC       FN (dimeric or cross-linked multimeric forms), made by fibroblasts,
CC       epithelial and other cell types, is deposited as fibrils in the
CC       extracellular matrix. Ugl-Y1, Ugl-Y2 and Ugl-Y3 are found in urine
CC       (PubMed:17614963). {ECO:0000269|PubMed:17614963,
CC       ECO:0000269|PubMed:29777959, ECO:0000269|PubMed:3584091}.
CC   -!- DEVELOPMENTAL STAGE: Expressed between 12 and 19 weeks post-conception
CC       (WPC) in Bruch's membrane, with expression in the choroid evident from
CC       14 WPC onwards (at protein level) (PubMed:29777959). Expressed in the
CC       inner limiting membrane at 17 WPC (at protein level) (PubMed:29777959).
CC       Ugl-Y1, Ugl-Y2 and Ugl-Y3 are present in the urine from 0 to 17 years
CC       of age (PubMed:17614963, PubMed:3584091). {ECO:0000269|PubMed:17614963,
CC       ECO:0000269|PubMed:29777959, ECO:0000269|PubMed:3584091}.
CC   -!- PTM: Sulfated. {ECO:0000269|PubMed:2414772}.
CC   -!- PTM: It is not known whether both or only one of Thr-2155 and Thr-2156
CC       are/is glycosylated. {ECO:0000269|PubMed:11285216,
CC       ECO:0000269|PubMed:14760718, ECO:0000269|PubMed:16037490,
CC       ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:17614963,
CC       ECO:0000269|PubMed:19139490, ECO:0000269|PubMed:19159218,
CC       ECO:0000269|PubMed:2012601, ECO:0000269|PubMed:3584091}.
CC   -!- PTM: Forms covalent cross-links mediated by a transglutaminase, such as
CC       F13A or TGM2, between a glutamine and the epsilon-amino group of a
CC       lysine residue, forming homopolymers and heteropolymers (e.g.
CC       fibrinogen-fibronectin, collagen-fibronectin heteropolymers).
CC       {ECO:0000250|UniProtKB:P11276}.
CC   -!- PTM: Phosphorylated by FAM20C in the extracellular medium.
CC       {ECO:0000269|PubMed:26091039}.
CC   -!- PTM: Proteolytic processing produces the C-terminal NC1 peptide,
CC       anastellin. {ECO:0000305|PubMed:8114919}.
CC   -!- PTM: Some lysine residues are oxidized to allysine by LOXL3, promoting
CC       fibronectin activation and matrix formation.
CC       {ECO:0000250|UniProtKB:P11276}.
CC   -!- PTM: Serotonylated on Gln residues by TGM2 in response to hypoxia.
CC       {ECO:0000250|UniProtKB:P07589}.
CC   -!- DISEASE: Glomerulopathy with fibronectin deposits 2 (GFND2)
CC       [MIM:601894]: Genetically heterogeneous autosomal dominant disorder
CC       characterized clinically by proteinuria, microscopic hematuria, and
CC       hypertension that leads to end-stage renal failure in the second to
CC       fifth decade of life. {ECO:0000269|PubMed:18268355}. Note=The disease
CC       is caused by variants affecting the gene represented in this entry.
CC   -!- DISEASE: Spondylometaphyseal dysplasia, corner fracture type (SMDCF)
CC       [MIM:184255]: An autosomal dominant form of spondylometaphyseal
CC       dysplasia, a group of short stature disorders distinguished by
CC       abnormalities in the vertebrae and the metaphyses of the tubular bones.
CC       SMDCF is characterized by flake-like, triangular, or curvilinear
CC       ossification centers at the edges of irregular metaphyses that simulate
CC       fractures. These corner fractures involve the distal tibia, the ulnar
CC       aspect of the distal radius, the proximal humerus, and the proximal
CC       femur. They represent irregular ossification at the growth plates and
CC       secondary ossification centers. {ECO:0000269|PubMed:29100092}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: [Isoform 16]: Expressed by fetal and tumor-associated
CC       cells. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA52463.1; Type=Erroneous translation; Evidence={ECO:0000305};
CC       Sequence=AAX76513.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=BAD93077.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAD91166.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAD97964.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAD97965.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAD97984.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAE45847.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAH18136.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Fibronectin entry;
CC       URL="https://en.wikipedia.org/wiki/Fibronectin";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ276395; CAC20427.1; -; mRNA.
DR   EMBL; AJ535086; CAD59389.1; -; mRNA.
DR   EMBL; AJ849445; CAH60958.1; -; mRNA.
DR   EMBL; AB191261; BAD52437.1; -; mRNA.
DR   EMBL; AB209840; BAD93077.1; ALT_INIT; mRNA.
DR   EMBL; AL832202; CAD91166.1; ALT_INIT; mRNA.
DR   EMBL; BX537590; CAD97791.1; -; mRNA.
DR   EMBL; BX538017; CAD97964.1; ALT_INIT; mRNA.
DR   EMBL; BX538018; CAD97965.1; ALT_INIT; mRNA.
DR   EMBL; BX538045; CAD97984.1; ALT_INIT; mRNA.
DR   EMBL; BX640608; CAE45714.1; -; mRNA.
DR   EMBL; BX640731; CAE45847.1; ALT_INIT; mRNA.
DR   EMBL; BX640875; CAE45932.1; -; mRNA.
DR   EMBL; BX640920; CAE45958.1; -; mRNA.
DR   EMBL; CR749281; CAH18136.1; ALT_INIT; mRNA.
DR   EMBL; CR749316; CAH18171.1; -; mRNA.
DR   EMBL; CR749317; CAH18172.1; -; mRNA.
DR   EMBL; AC012462; AAX76513.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AC073284; AAY24063.1; -; Genomic_DNA.
DR   EMBL; CH471063; EAW70536.1; -; Genomic_DNA.
DR   EMBL; BC117176; AAI17177.1; -; mRNA.
DR   EMBL; BC143763; AAI43764.1; -; mRNA.
DR   EMBL; M15801; AAA53376.1; -; Genomic_DNA.
DR   EMBL; AF312399; AAG30571.1; -; mRNA.
DR   EMBL; X02761; CAA26536.1; -; mRNA.
DR   EMBL; U41850; AAD00014.1; -; mRNA.
DR   EMBL; U42404; AAD00015.1; -; mRNA.
DR   EMBL; U42592; AAD00017.1; -; mRNA.
DR   EMBL; U42593; AAD00018.1; -; mRNA.
DR   EMBL; U42594; AAD00019.1; -; mRNA.
DR   EMBL; U42455; AAD09448.1; -; mRNA.
DR   EMBL; U42456; AAD09449.1; -; mRNA.
DR   EMBL; U42458; AAD09450.1; -; mRNA.
DR   EMBL; U42457; AAD04751.1; -; mRNA.
DR   EMBL; X07718; CAB52436.1; -; Genomic_DNA.
DR   EMBL; X07717; CAB52437.1; -; Genomic_DNA.
DR   EMBL; M18179; AAA52461.1; -; Genomic_DNA.
DR   EMBL; M18177; AAA52461.1; JOINED; Genomic_DNA.
DR   EMBL; M18178; AAA52461.1; JOINED; Genomic_DNA.
DR   EMBL; M12549; AAA58483.1; -; Genomic_DNA.
DR   EMBL; M10905; AAA52462.1; -; mRNA.
DR   EMBL; M14059; AAA52463.1; ALT_SEQ; mRNA.
DR   EMBL; AJ320525; CAC86914.1; -; mRNA.
DR   EMBL; AJ320526; CAC86915.1; -; mRNA.
DR   EMBL; AJ320527; CAC86916.1; -; mRNA.
DR   EMBL; M27589; AAA52465.1; -; mRNA.
DR   EMBL; X04530; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS2399.1; -. [P02751-3]
DR   CCDS; CCDS2400.1; -. [P02751-10]
DR   CCDS; CCDS42813.1; -. [P02751-8]
DR   CCDS; CCDS42814.1; -. [P02751-15]
DR   CCDS; CCDS46510.1; -. [P02751-17]
DR   CCDS; CCDS46512.1; -. [P02751-16]
DR   CCDS; CCDS77522.1; -. [P02751-9]
DR   CCDS; CCDS77523.1; -. [P02751-14]
DR   CCDS; CCDS77525.1; -. [P02751-13]
DR   CCDS; CCDS77526.1; -. [P02751-7]
DR   CCDS; CCDS92940.1; -. [P02751-1]
DR   PIR; A26460; FNHU.
DR   PIR; I52394; I52394.
DR   PIR; S00848; S00848.
DR   RefSeq; NP_001293058.2; NM_001306129.2. [P02751-7]
DR   RefSeq; NP_001293059.2; NM_001306130.2. [P02751-13]
DR   RefSeq; NP_001293060.2; NM_001306131.2. [P02751-14]
DR   RefSeq; NP_001293061.2; NM_001306132.2. [P02751-9]
DR   RefSeq; NP_001352447.1; NM_001365518.2. [P02751-1]
DR   RefSeq; NP_002017.2; NM_002026.4. [P02751-3]
DR   RefSeq; NP_473375.2; NM_054034.2. [P02751-16]
DR   RefSeq; NP_997639.2; NM_212474.3. [P02751-10]
DR   RefSeq; NP_997641.2; NM_212476.3. [P02751-8]
DR   RefSeq; NP_997643.2; NM_212478.3. [P02751-17]
DR   RefSeq; NP_997647.2; NM_212482.4. [P02751-15]
DR   RefSeq; XP_005246463.1; XM_005246406.1.
DR   PDB; 1E88; NMR; -; A=305-464.
DR   PDB; 1E8B; NMR; -; A=305-464.
DR   PDB; 1FBR; NMR; -; A=183-275.
DR   PDB; 1FNA; X-ray; 1.80 A; A=1543-1633.
DR   PDB; 1FNF; X-ray; 2.00 A; A=1173-1265, A=1357-1631.
DR   PDB; 1FNH; X-ray; 2.80 A; A=1812-2082.
DR   PDB; 1J8K; NMR; -; A=1722-1815.
DR   PDB; 1O9A; NMR; -; A=48-140.
DR   PDB; 1OWW; NMR; -; A=608-701.
DR   PDB; 1Q38; NMR; -; A=631-705.
DR   PDB; 1QGB; NMR; -; A=48-140.
DR   PDB; 1QO6; NMR; -; A=305-405.
DR   PDB; 1TTF; NMR; -; A=1538-1631.
DR   PDB; 1TTG; NMR; -; A=1538-1631.
DR   PDB; 2CG6; X-ray; 1.55 A; A=93-182.
DR   PDB; 2CG7; X-ray; 1.20 A; A=93-182.
DR   PDB; 2CK2; X-ray; 2.00 A; A/B=1538-1633.
DR   PDB; 2CKU; NMR; -; A=93-182.
DR   PDB; 2EC3; NMR; -; A=2330-2390.
DR   PDB; 2FN2; NMR; -; A=406-464.
DR   PDB; 2FNB; NMR; -; A=1266-1356.
DR   PDB; 2GEE; X-ray; 2.01 A; A=1266-1447.
DR   PDB; 2H41; NMR; -; A=721-809.
DR   PDB; 2H45; NMR; -; A=721-809.
DR   PDB; 2HA1; NMR; -; A=609-809.
DR   PDB; 2MNU; NMR; -; A=907-995.
DR   PDB; 2N1K; NMR; -; A=808-905.
DR   PDB; 2OCF; X-ray; 2.95 A; D=1539-1631.
DR   PDB; 2RKY; X-ray; 1.80 A; A/C=183-275.
DR   PDB; 2RKZ; X-ray; 2.00 A; A/B/C/D/E/F=93-182.
DR   PDB; 2RL0; X-ray; 2.00 A; A/B/D/F/I/K=184-272.
DR   PDB; 3CAL; X-ray; 1.70 A; A/C=93-182.
DR   PDB; 3EJH; X-ray; 2.10 A; A/B=516-608.
DR   PDB; 3GXE; X-ray; 2.60 A; A/B=516-608.
DR   PDB; 3M7P; X-ray; 2.50 A; A=297-604.
DR   PDB; 3MQL; X-ray; 3.00 A; A=308-515.
DR   PDB; 3R8Q; X-ray; 2.40 A; A=1812-2082.
DR   PDB; 3T1W; X-ray; 2.40 A; A=1173-1539.
DR   PDB; 3ZRZ; X-ray; 1.70 A; A/B=93-182.
DR   PDB; 4GH7; X-ray; 2.60 A; B/D=1173-1447.
DR   PDB; 4JE4; X-ray; 2.31 A; B=1539-1631.
DR   PDB; 4JEG; X-ray; 2.30 A; B=1539-1631.
DR   PDB; 4LXO; X-ray; 1.42 A; A/B=1448-1631.
DR   PDB; 4MMX; X-ray; 3.32 A; C=1539-1631.
DR   PDB; 4MMY; X-ray; 3.18 A; C=1539-1631.
DR   PDB; 4MMZ; X-ray; 3.10 A; C=1539-1629.
DR   PDB; 4PZ5; X-ray; 1.96 A; A=93-182.
DR   PDB; 5DC0; X-ray; 2.23 A; A=1540-1631.
DR   PDB; 5DC4; X-ray; 1.48 A; B=1539-1631.
DR   PDB; 5DC9; X-ray; 1.56 A; B=1537-1631.
DR   PDB; 5DFT; X-ray; 2.50 A; A/B/C/D/E/F/G/H/I/J=1638-1726.
DR   PDB; 5J6Z; NMR; -; A=806-834, B=631-705.
DR   PDB; 5J7C; X-ray; 2.54 A; C/D=1540-1631.
DR   PDB; 5M0A; NMR; -; A=2199-2284.
DR   PDB; 5N47; X-ray; 3.00 A; B=1267-1448, D/F=1173-1448.
DR   PDB; 5N48; X-ray; 1.60 A; B/D=907-995.
DR   PDB; 6HNF; NMR; -; A=1995-2082.
DR   PDB; 6MFA; X-ray; 1.75 A; A=903-1268.
DR   PDB; 6MSV; X-ray; 2.40 A; A/B/C/D/E/F/G/H/I/J/K/L=1085-1173.
DR   PDB; 6NAJ; X-ray; 3.10 A; C=1539-1629.
DR   PDB; 6XAX; X-ray; 2.40 A; A/B=1630-1903.
DR   PDB; 6XAY; X-ray; 2.48 A; A/B/C/D=1538-1903.
DR   PDB; 7NWL; EM; 3.10 A; C=1173-1631.
DR   PDB; 8PEQ; X-ray; 2.32 A; A/B/C=1174-1447.
DR   PDBsum; 1E88; -.
DR   PDBsum; 1E8B; -.
DR   PDBsum; 1FBR; -.
DR   PDBsum; 1FNA; -.
DR   PDBsum; 1FNF; -.
DR   PDBsum; 1FNH; -.
DR   PDBsum; 1J8K; -.
DR   PDBsum; 1O9A; -.
DR   PDBsum; 1OWW; -.
DR   PDBsum; 1Q38; -.
DR   PDBsum; 1QGB; -.
DR   PDBsum; 1QO6; -.
DR   PDBsum; 1TTF; -.
DR   PDBsum; 1TTG; -.
DR   PDBsum; 2CG6; -.
DR   PDBsum; 2CG7; -.
DR   PDBsum; 2CK2; -.
DR   PDBsum; 2CKU; -.
DR   PDBsum; 2EC3; -.
DR   PDBsum; 2FN2; -.
DR   PDBsum; 2FNB; -.
DR   PDBsum; 2GEE; -.
DR   PDBsum; 2H41; -.
DR   PDBsum; 2H45; -.
DR   PDBsum; 2HA1; -.
DR   PDBsum; 2MNU; -.
DR   PDBsum; 2N1K; -.
DR   PDBsum; 2OCF; -.
DR   PDBsum; 2RKY; -.
DR   PDBsum; 2RKZ; -.
DR   PDBsum; 2RL0; -.
DR   PDBsum; 3CAL; -.
DR   PDBsum; 3EJH; -.
DR   PDBsum; 3GXE; -.
DR   PDBsum; 3M7P; -.
DR   PDBsum; 3MQL; -.
DR   PDBsum; 3R8Q; -.
DR   PDBsum; 3T1W; -.
DR   PDBsum; 3ZRZ; -.
DR   PDBsum; 4GH7; -.
DR   PDBsum; 4JE4; -.
DR   PDBsum; 4JEG; -.
DR   PDBsum; 4LXO; -.
DR   PDBsum; 4MMX; -.
DR   PDBsum; 4MMY; -.
DR   PDBsum; 4MMZ; -.
DR   PDBsum; 4PZ5; -.
DR   PDBsum; 5DC0; -.
DR   PDBsum; 5DC4; -.
DR   PDBsum; 5DC9; -.
DR   PDBsum; 5DFT; -.
DR   PDBsum; 5J6Z; -.
DR   PDBsum; 5J7C; -.
DR   PDBsum; 5M0A; -.
DR   PDBsum; 5N47; -.
DR   PDBsum; 5N48; -.
DR   PDBsum; 6HNF; -.
DR   PDBsum; 6MFA; -.
DR   PDBsum; 6MSV; -.
DR   PDBsum; 6NAJ; -.
DR   PDBsum; 6XAX; -.
DR   PDBsum; 6XAY; -.
DR   PDBsum; 7NWL; -.
DR   PDBsum; 8PEQ; -.
DR   AlphaFoldDB; P02751; -.
DR   EMDB; EMD-12634; -.
DR   SMR; P02751; -.
DR   BioGRID; 108621; 816.
DR   ComplexPortal; CPX-6232; Fibronectin complex.
DR   CORUM; P02751; -.
DR   DIP; DIP-29547N; -.
DR   ELM; P02751; -.
DR   FunCoup; P02751; 1464.
DR   IntAct; P02751; 569.
DR   MINT; P02751; -.
DR   STRING; 9606.ENSP00000346839; -.
DR   BindingDB; P02751; -.
DR   ChEMBL; CHEMBL3810; -.
DR   DrugBank; DB06245; Lanoteplase.
DR   DrugBank; DB08888; Ocriplasmin.
DR   DrugBank; DB01593; Zinc.
DR   DrugBank; DB14487; Zinc acetate.
DR   DrugBank; DB14533; Zinc chloride.
DR   DrugBank; DB14548; Zinc sulfate, unspecified form.
DR   CarbonylDB; P02751; -.
DR   GlyConnect; 161; 100 N-Linked glycans (6 sites).
DR   GlyCosmos; P02751; 20 sites, 130 glycans.
DR   GlyGen; P02751; 38 sites, 265 N-linked glycans (8 sites), 7 O-linked glycans (19 sites).
DR   iPTMnet; P02751; -.
DR   MetOSite; P02751; -.
DR   PhosphoSitePlus; P02751; -.
DR   SwissPalm; P02751; -.
DR   BioMuta; FN1; -.
DR   DMDM; 300669710; -.
DR   CPTAC; non-CPTAC-1122; -.
DR   CPTAC; non-CPTAC-2666; -.
DR   jPOST; P02751; -.
DR   MassIVE; P02751; -.
DR   PaxDb; 9606-ENSP00000346839; -.
DR   PeptideAtlas; P02751; -.
DR   ProteomicsDB; 19829; -.
DR   ProteomicsDB; 20230; -.
DR   ProteomicsDB; 51567; -. [P02751-1]
DR   ProteomicsDB; 51568; -. [P02751-10]
DR   ProteomicsDB; 51569; -. [P02751-11]
DR   ProteomicsDB; 51570; -. [P02751-12]
DR   ProteomicsDB; 51571; -. [P02751-13]
DR   ProteomicsDB; 51572; -. [P02751-14]
DR   ProteomicsDB; 51573; -. [P02751-15]
DR   ProteomicsDB; 51574; -. [P02751-2]
DR   ProteomicsDB; 51575; -. [P02751-3]
DR   ProteomicsDB; 51576; -. [P02751-4]
DR   ProteomicsDB; 51577; -. [P02751-5]
DR   ProteomicsDB; 51578; -. [P02751-6]
DR   ProteomicsDB; 51579; -. [P02751-7]
DR   ProteomicsDB; 51580; -. [P02751-8]
DR   ProteomicsDB; 51581; -. [P02751-9]
DR   Pumba; P02751; -.
DR   ABCD; P02751; 21 sequenced antibodies.
DR   Antibodypedia; 3522; 2938 antibodies from 49 providers.
DR   DNASU; 2335; -.
DR   Ensembl; ENST00000323926.10; ENSP00000323534.6; ENSG00000115414.21. [P02751-7]
DR   Ensembl; ENST00000336916.8; ENSP00000338200.4; ENSG00000115414.21. [P02751-3]
DR   Ensembl; ENST00000354785.11; ENSP00000346839.4; ENSG00000115414.21. [P02751-15]
DR   Ensembl; ENST00000356005.8; ENSP00000348285.4; ENSG00000115414.21. [P02751-8]
DR   Ensembl; ENST00000357867.8; ENSP00000350534.4; ENSG00000115414.21. [P02751-10]
DR   Ensembl; ENST00000359671.5; ENSP00000352696.1; ENSG00000115414.21. [P02751-1]
DR   Ensembl; ENST00000421182.5; ENSP00000394423.1; ENSG00000115414.21. [P02751-9]
DR   Ensembl; ENST00000426059.1; ENSP00000398907.1; ENSG00000115414.21. [P02751-16]
DR   Ensembl; ENST00000432072.6; ENSP00000399538.2; ENSG00000115414.21. [P02751-13]
DR   Ensembl; ENST00000443816.5; ENSP00000415018.1; ENSG00000115414.21. [P02751-14]
DR   Ensembl; ENST00000446046.5; ENSP00000410422.1; ENSG00000115414.21. [P02751-17]
DR   GeneID; 2335; -.
DR   KEGG; hsa:2335; -.
DR   MANE-Select; ENST00000354785.11; ENSP00000346839.4; NM_212482.4; NP_997647.2.
DR   UCSC; uc002vfa.4; human. [P02751-15]
DR   AGR; HGNC:3778; -.
DR   CTD; 2335; -.
DR   DisGeNET; 2335; -.
DR   GeneCards; FN1; -.
DR   GeneReviews; FN1; -.
DR   HGNC; HGNC:3778; FN1.
DR   HPA; ENSG00000115414; Tissue enhanced (liver, placenta).
DR   MalaCards; FN1; -.
DR   MIM; 135600; gene.
DR   MIM; 184255; phenotype.
DR   MIM; 601894; phenotype.
DR   OpenTargets; ENSG00000115414; -.
DR   Orphanet; 84090; Fibronectin glomerulopathy.
DR   Orphanet; 93315; Spondylometaphyseal dysplasia, 'corner fracture' type.
DR   VEuPathDB; HostDB:ENSG00000115414; -.
DR   GeneTree; ENSGT00940000155126; -.
DR   HOGENOM; CLU_000916_0_0_1; -.
DR   InParanoid; P02751; -.
DR   OMA; GHCITDS; -.
DR   OrthoDB; 261433at2759; -.
DR   PAN-GO; P02751; 10 GO annotations based on evolutionary models.
DR   PhylomeDB; P02751; -.
DR   PathwayCommons; P02751; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-1474228; Degradation of the extracellular matrix.
DR   Reactome; R-HSA-1474244; Extracellular matrix organization.
DR   Reactome; R-HSA-1566977; Fibronectin matrix formation.
DR   Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
DR   Reactome; R-HSA-2129379; Molecules associated with elastic fibres.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-3000170; Syndecan interactions.
DR   Reactome; R-HSA-3000171; Non-integrin membrane-ECM interactions.
DR   Reactome; R-HSA-3000178; ECM proteoglycans.
DR   Reactome; R-HSA-354192; Integrin signaling.
DR   Reactome; R-HSA-354194; GRB2:SOS provides linkage to MAPK signaling for Integrins.
DR   Reactome; R-HSA-372708; p130Cas linkage to MAPK signaling for integrins.
DR   Reactome; R-HSA-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   Reactome; R-HSA-8874081; MET activates PTK2 signaling.
DR   Reactome; R-HSA-8957275; Post-translational protein phosphorylation.
DR   Reactome; R-HSA-9634597; GPER1 signaling.
DR   Reactome; R-HSA-9649948; Signaling downstream of RAS mutants.
DR   Reactome; R-HSA-9656223; Signaling by RAF1 mutants.
DR   Reactome; R-HSA-9700645; ALK mutants bind TKIs.
DR   Reactome; R-HSA-9725370; Signaling by ALK fusions and activated point mutants.
DR   Reactome; R-HSA-9860927; Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells.
DR   SignaLink; P02751; -.
DR   SIGNOR; P02751; -.
DR   BioGRID-ORCS; 2335; 11 hits in 1162 CRISPR screens.
DR   ChiTaRS; FN1; human.
DR   EvolutionaryTrace; P02751; -.
DR   GeneWiki; Fibronectin; -.
DR   GenomeRNAi; 2335; -.
DR   Pharos; P02751; Tchem.
DR   PRO; PR:P02751; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P02751; protein.
DR   Bgee; ENSG00000115414; Expressed in synovial joint and 202 other cell types or tissues.
DR   ExpressionAtlas; P02751; baseline and differential.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0005604; C:basement membrane; IEA:Ensembl.
DR   GO; GO:0072562; C:blood microparticle; HDA:UniProtKB.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; IDA:UniProtKB.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005793; C:endoplasmic reticulum-Golgi intermediate compartment; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031012; C:extracellular matrix; IDA:MGI.
DR   GO; GO:0005576; C:extracellular region; HDA:BHF-UCL.
DR   GO; GO:0005615; C:extracellular space; IDA:CAFA.
DR   GO; GO:0005577; C:fibrinogen complex; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0005518; F:collagen binding; NAS:UniProtKB.
DR   GO; GO:0005201; F:extracellular matrix structural constituent; HDA:BHF-UCL.
DR   GO; GO:0008201; F:heparin binding; NAS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0005178; F:integrin binding; IDA:UniProtKB.
DR   GO; GO:0016504; F:peptidase activator activity; IEA:Ensembl.
DR   GO; GO:0002020; F:protease binding; IPI:BHF-UCL.
DR   GO; GO:0043394; F:proteoglycan binding; IDA:MGI.
DR   GO; GO:0048018; F:receptor ligand activity; IEA:Ensembl.
DR   GO; GO:0005102; F:signaling receptor binding; IDA:UniProtKB.
DR   GO; GO:0006953; P:acute-phase response; IEA:UniProtKB-KW.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0051702; P:biological process involved in interaction with symbiont; IDA:CAFA.
DR   GO; GO:0007161; P:calcium-independent cell-matrix adhesion; IEA:Ensembl.
DR   GO; GO:0007155; P:cell adhesion; NAS:UniProtKB.
DR   GO; GO:0007160; P:cell-matrix adhesion; IBA:GO_Central.
DR   GO; GO:0007044; P:cell-substrate junction assembly; IBA:GO_Central.
DR   GO; GO:0035987; P:endodermal cell differentiation; IDA:UniProtKB.
DR   GO; GO:0043542; P:endothelial cell migration; IDA:BHF-UCL.
DR   GO; GO:0007507; P:heart development; IBA:GO_Central.
DR   GO; GO:0033622; P:integrin activation; IMP:UniProtKB.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0150102; P:negative regulation of monocyte activation; IDA:UniProtKB.
DR   GO; GO:0071635; P:negative regulation of transforming growth factor beta production; IDA:UniProtKB.
DR   GO; GO:0007399; P:nervous system development; IBA:GO_Central.
DR   GO; GO:1901166; P:neural crest cell migration involved in autonomic nervous system development; IDA:MGI.
DR   GO; GO:0018149; P:peptide cross-linking; IDA:BHF-UCL.
DR   GO; GO:0045773; P:positive regulation of axon extension; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IDA:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:BHF-UCL.
DR   GO; GO:1904237; P:positive regulation of substrate-dependent cell migration, cell attachment to substrate; IDA:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IEA:UniProtKB-KW.
DR   GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0001932; P:regulation of protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0014850; P:response to muscle activity; IEA:Ensembl.
DR   GO; GO:0009611; P:response to wounding; NAS:UniProtKB.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IDA:BHF-UCL.
DR   GO; GO:0042060; P:wound healing; IEA:Ensembl.
DR   CDD; cd00061; FN1; 12.
DR   CDD; cd00062; FN2; 2.
DR   CDD; cd00063; FN3; 17.
DR   FunFam; 2.10.70.10:FF:000004; Fibronectin 1; 1.
DR   FunFam; 2.10.70.10:FF:000006; Fibronectin 1; 3.
DR   FunFam; 2.10.70.10:FF:000007; Fibronectin 1; 2.
DR   FunFam; 2.10.70.10:FF:000018; Fibronectin 1; 1.
DR   FunFam; 2.10.70.10:FF:000027; Fibronectin 1; 1.
DR   FunFam; 2.60.40.10:FF:000099; Fibronectin 1; 3.
DR   FunFam; 2.60.40.10:FF:000417; Fibronectin 1; 1.
DR   FunFam; 2.60.40.10:FF:000579; Fibronectin 1; 1.
DR   FunFam; 2.60.40.10:FF:000622; Fibronectin 1; 1.
DR   FunFam; 2.60.40.10:FF:001069; Fibronectin 1; 1.
DR   FunFam; 2.10.10.10:FF:000001; Fibronectin 1a isoform 1; 2.
DR   FunFam; 2.10.70.10:FF:000017; Fibronectin isoform X1; 1.
DR   FunFam; 2.60.40.10:FF:000227; Fibronectin isoform X1; 1.
DR   FunFam; 2.10.70.10:FF:000020; fibronectin isoform X1; 1.
DR   FunFam; 2.10.70.10:FF:000021; fibronectin isoform X1; 1.
DR   FunFam; 2.10.70.10:FF:000022; fibronectin isoform X1; 1.
DR   FunFam; 2.60.40.10:FF:000275; fibronectin isoform X1; 1.
DR   FunFam; 2.60.40.10:FF:000300; fibronectin isoform X1; 1.
DR   FunFam; 2.60.40.10:FF:000306; fibronectin isoform X1; 1.
DR   FunFam; 2.60.40.10:FF:000317; fibronectin isoform X1; 1.
DR   FunFam; 2.60.40.10:FF:000336; fibronectin isoform X1; 1.
DR   FunFam; 2.60.40.10:FF:000364; fibronectin isoform X1; 1.
DR   FunFam; 2.60.40.10:FF:000382; fibronectin isoform X1; 1.
DR   FunFam; 2.60.40.10:FF:000447; fibronectin isoform X1; 1.
DR   FunFam; 2.60.40.10:FF:000433; fibronectin isoform X5; 1.
DR   Gene3D; 2.10.70.10; Complement Module, domain 1; 12.
DR   Gene3D; 2.10.10.10; Fibronectin, type II, collagen-binding; 2.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 17.
DR   InterPro; IPR050991; ECM_Regulatory_Proteins.
DR   InterPro; IPR000083; Fibronectin_type1.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR000562; FN_type2_dom.
DR   InterPro; IPR036943; FN_type2_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013806; Kringle-like.
DR   PANTHER; PTHR46708:SF8; FIBRONECTIN; 1.
DR   PANTHER; PTHR46708; TENASCIN; 1.
DR   Pfam; PF00039; fn1; 11.
DR   Pfam; PF00040; fn2; 2.
DR   Pfam; PF00041; fn3; 17.
DR   PRINTS; PR00013; FNTYPEII.
DR   SMART; SM00058; FN1; 12.
DR   SMART; SM00059; FN2; 2.
DR   SMART; SM00060; FN3; 17.
DR   SUPFAM; SSF49265; Fibronectin type III; 11.
DR   SUPFAM; SSF57603; FnI-like domain; 12.
DR   SUPFAM; SSF57440; Kringle-like; 2.
DR   PROSITE; PS00022; EGF_1; 2.
DR   PROSITE; PS01253; FN1_1; 12.
DR   PROSITE; PS51091; FN1_2; 12.
DR   PROSITE; PS00023; FN2_1; 2.
DR   PROSITE; PS51092; FN2_2; 2.
DR   PROSITE; PS50853; FN3; 17.
DR   neXtProt; NX_P02751; -.
DR   PharmGKB; PA28194; -.
DR   TreeFam; TF329915; -.
PE   1: Evidence at protein level;
KW   3D-structure; Acute phase; Alternative splicing; Angiogenesis;
KW   Cell adhesion; Cell shape; Direct protein sequencing; Disease variant;
KW   Disulfide bond; Dwarfism; Extracellular matrix; Glycoprotein;
KW   Heparin-binding; Isopeptide bond; Oxidation; Phosphoprotein;
KW   Proteomics identification; Pyrrolidone carboxylic acid; Reference proteome;
KW   Repeat; Secreted; Signal; Sulfation.
FT   SIGNAL          1..31
FT                   /evidence="ECO:0000269|PubMed:6630202"
FT   CHAIN           32..2477
FT                   /note="Fibronectin"
FT                   /id="PRO_0000019235"
FT   CHAIN           627..702
FT                   /note="Anastellin"
FT                   /id="PRO_0000390479"
FT   CHAIN           723..911
FT                   /note="Ugl-Y1"
FT                   /evidence="ECO:0000269|PubMed:3584091,
FT                   ECO:0000303|PubMed:17614963"
FT                   /id="PRO_0000300249"
FT   CHAIN           723..903
FT                   /note="Ugl-Y2"
FT                   /id="PRO_0000300250"
FT   CHAIN           723..?
FT                   /note="Ugl-Y3"
FT                   /id="PRO_0000300251"
FT   DOMAIN          50..90
FT                   /note="Fibronectin type-I 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DOMAIN          95..138
FT                   /note="Fibronectin type-I 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DOMAIN          139..182
FT                   /note="Fibronectin type-I 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DOMAIN          184..228
FT                   /note="Fibronectin type-I 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DOMAIN          229..273
FT                   /note="Fibronectin type-I 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DOMAIN          306..345
FT                   /note="Fibronectin type-I 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DOMAIN          355..403
FT                   /note="Fibronectin type-II 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478,
FT                   ECO:0000255|PROSITE-ProRule:PRU00479"
FT   DOMAIN          415..463
FT                   /note="Fibronectin type-II 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478,
FT                   ECO:0000255|PROSITE-ProRule:PRU00479"
FT   DOMAIN          468..511
FT                   /note="Fibronectin type-I 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DOMAIN          516..558
FT                   /note="Fibronectin type-I 8"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DOMAIN          559..602
FT                   /note="Fibronectin type-I 9"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DOMAIN          610..702
FT                   /note="Fibronectin type-III 1"
FT   DOMAIN          722..812
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316,
FT                   ECO:0000255|PROSITE-ProRule:PRU00478, ECO:0000255|PROSITE-
FT                   ProRule:PRU00479"
FT   DOMAIN          813..904
FT                   /note="Fibronectin type-III 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316,
FT                   ECO:0000255|PROSITE-ProRule:PRU00478, ECO:0000255|PROSITE-
FT                   ProRule:PRU00479"
FT   DOMAIN          909..998
FT                   /note="Fibronectin type-III 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316,
FT                   ECO:0000255|PROSITE-ProRule:PRU00478, ECO:0000255|PROSITE-
FT                   ProRule:PRU00479"
FT   DOMAIN          999..1088
FT                   /note="Fibronectin type-III 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316,
FT                   ECO:0000255|PROSITE-ProRule:PRU00478, ECO:0000255|PROSITE-
FT                   ProRule:PRU00479"
FT   DOMAIN          1089..1175
FT                   /note="Fibronectin type-III 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316,
FT                   ECO:0000255|PROSITE-ProRule:PRU00478, ECO:0000255|PROSITE-
FT                   ProRule:PRU00479"
FT   DOMAIN          1176..1270
FT                   /note="Fibronectin type-III 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316,
FT                   ECO:0000255|PROSITE-ProRule:PRU00478, ECO:0000255|PROSITE-
FT                   ProRule:PRU00479"
FT   DOMAIN          1271..1359
FT                   /note="Fibronectin type-III 8; extra domain B"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316,
FT                   ECO:0000255|PROSITE-ProRule:PRU00478, ECO:0000255|PROSITE-
FT                   ProRule:PRU00479"
FT   DOMAIN          1360..1452
FT                   /note="Fibronectin type-III 9"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316,
FT                   ECO:0000255|PROSITE-ProRule:PRU00478, ECO:0000255|PROSITE-
FT                   ProRule:PRU00479"
FT   DOMAIN          1453..1540
FT                   /note="Fibronectin type-III 10"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1541..1634
FT                   /note="Fibronectin type-III 11"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1635..1726
FT                   /note="Fibronectin type-III 12"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316,
FT                   ECO:0000255|PROSITE-ProRule:PRU00478, ECO:0000255|PROSITE-
FT                   ProRule:PRU00479"
FT   DOMAIN          1727..1814
FT                   /note="Fibronectin type-III 13; extra domain A"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1815..1908
FT                   /note="Fibronectin type-III 14"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1909..1995
FT                   /note="Fibronectin type-III 15"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1996..2086
FT                   /note="Fibronectin type-III 16"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          2194..2288
FT                   /note="Fibronectin type-III 17"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          2295..2339
FT                   /note="Fibronectin type-I 10"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DOMAIN          2340..2382
FT                   /note="Fibronectin type-I 11"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DOMAIN          2384..2427
FT                   /note="Fibronectin type-I 12"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DNA_BIND        907..1172
FT   REGION          27..48
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          52..272
FT                   /note="Fibrin- and heparin-binding 1"
FT                   /evidence="ECO:0000269|PubMed:7989369"
FT   REGION          123..142
FT                   /note="Required for binding to LILRB4"
FT                   /evidence="ECO:0000269|PubMed:34089617"
FT   REGION          308..608
FT                   /note="Collagen-binding"
FT   REGION          464..477
FT                   /note="Critical for collagen binding"
FT   REGION          1358..1631
FT                   /note="Cell-attachment"
FT   REGION          1660..1684
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1812..2082
FT                   /note="Heparin-binding 2"
FT   REGION          1904..2082
FT                   /note="Binds to FBLN1"
FT   REGION          2083..2202
FT                   /note="V region (type III connecting segment, IIICS)"
FT   REGION          2149..2169
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2297..2428
FT                   /note="Fibrin-binding 2"
FT   MOTIF           1615..1617
FT                   /note="Cell attachment site"
FT   COMPBIAS        1666..1683
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2150..2159
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            663
FT                   /note="Important for superfibronectin formation"
FT   SITE            666
FT                   /note="Important for superfibronectin formation"
FT   MOD_RES         32
FT                   /note="Pyrrolidone carboxylic acid"
FT                   /evidence="ECO:0000269|PubMed:6630202"
FT   MOD_RES         876
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         881
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         2454
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         2475
FT                   /note="Phosphoserine; by FAM20C"
FT                   /evidence="ECO:0000269|PubMed:26091039,
FT                   ECO:0007744|PubMed:17081983, ECO:0007744|PubMed:18318008,
FT                   ECO:0007744|PubMed:24275569"
FT   CARBOHYD        279
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000269|PubMed:16037490"
FT   CARBOHYD        430
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:11285216,
FT                   ECO:0000269|PubMed:16037490, ECO:0000269|PubMed:16335952"
FT   CARBOHYD        528
FT                   /note="N-linked (GlcNAc...) (complex) asparagine"
FT                   /evidence="ECO:0000269|PubMed:14760718,
FT                   ECO:0000269|PubMed:16037490, ECO:0000269|PubMed:16335952,
FT                   ECO:0000269|PubMed:19139490, ECO:0000269|PubMed:19159218"
FT   CARBOHYD        542
FT                   /note="N-linked (GlcNAc...) (complex) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16037490,
FT                   ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:19139490"
FT   CARBOHYD        877
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16037490,
FT                   ECO:0000269|PubMed:17614963"
FT   CARBOHYD        1007
FT                   /note="N-linked (GlcNAc...) (complex) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16037490,
FT                   ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:19139490,
FT                   ECO:0000269|PubMed:19159218"
FT   CARBOHYD        1244
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16037490,
FT                   ECO:0000269|PubMed:16335952"
FT   CARBOHYD        2199
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16037490"
FT   DISULFID        52..78
FT                   /evidence="ECO:0000269|PubMed:12736686"
FT   DISULFID        76..87
FT                   /evidence="ECO:0000269|PubMed:12736686"
FT   DISULFID        97..125
FT                   /evidence="ECO:0000269|PubMed:12736686,
FT                   ECO:0000269|PubMed:17368672"
FT   DISULFID        123..135
FT                   /evidence="ECO:0000269|PubMed:17368672"
FT   DISULFID        141..169
FT                   /evidence="ECO:0000269|PubMed:17368672"
FT   DISULFID        167..179
FT                   /evidence="ECO:0000269|PubMed:17368672"
FT   DISULFID        186..215
FT                   /evidence="ECO:0000269|PubMed:8308892"
FT   DISULFID        213..225
FT                   /evidence="ECO:0000269|PubMed:8308892"
FT   DISULFID        231..260
FT                   /evidence="ECO:0000269|PubMed:8308892"
FT   DISULFID        258..270
FT                   /evidence="ECO:0000269|PubMed:8308892"
FT   DISULFID        308..335
FT                   /evidence="ECO:0000269|PubMed:11285216"
FT   DISULFID        333..342
FT                   /evidence="ECO:0000269|PubMed:11285216"
FT   DISULFID        360..386
FT                   /evidence="ECO:0000269|PubMed:11285216"
FT   DISULFID        374..401
FT                   /evidence="ECO:0000269|PubMed:11285216"
FT   DISULFID        420..446
FT                   /evidence="ECO:0000269|PubMed:11285216"
FT   DISULFID        434..461
FT                   /evidence="ECO:0000269|PubMed:11285216"
FT   DISULFID        470..498
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DISULFID        496..508
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DISULFID        518..545
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DISULFID        543..555
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DISULFID        561..589
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DISULFID        587..599
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DISULFID        2297..2326
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DISULFID        2324..2336
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DISULFID        2342..2369
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DISULFID        2367..2379
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DISULFID        2386..2410
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DISULFID        2408..2424
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DISULFID        2458
FT                   /note="Interchain (with C-2462)"
FT   DISULFID        2462
FT                   /note="Interchain (with C-2458)"
FT   CROSSLNK        34
FT                   /note="Isoglutamyl lysine isopeptide (Gln-Lys) (interchain
FT                   with K-?)"
FT                   /evidence="ECO:0000250|UniProtKB:P11276"
FT   CROSSLNK        35
FT                   /note="Isoglutamyl lysine isopeptide (Gln-Lys) (interchain
FT                   with K-?)"
FT                   /evidence="ECO:0000250|UniProtKB:P11276"
FT   CROSSLNK        47
FT                   /note="Isoglutamyl lysine isopeptide (Gln-Lys) (interchain
FT                   with K-?)"
FT                   /evidence="ECO:0000250|UniProtKB:P11276"
FT   VAR_SEQ         368..386
FT                   /note="GRTFYSCTTEGRQDGHLWC -> DRTD (in isoform 2)"
FT                   /id="VSP_060343"
FT   VAR_SEQ         648..657
FT                   /note="KNSVGRWKEA -> VSIPPRNLGY (in isoform 2 and isoform
FT                   16)"
FT                   /id="VSP_060344"
FT   VAR_SEQ         658..2477
FT                   /note="Missing (in isoform 2 and isoform 16)"
FT                   /id="VSP_060345"
FT   VAR_SEQ         1256..1578
FT                   /note="Missing (in isoform 12)"
FT                   /id="VSP_060346"
FT   VAR_SEQ         1266..1356
FT                   /note="Missing (in isoform 1, isoform 3, isoform 4, isoform
FT                   5, isoform 6, isoform 8, isoform 9, isoform 10, isoform 14
FT                   and isoform 17)"
FT                   /id="VSP_060347"
FT   VAR_SEQ         1367..1457
FT                   /note="Missing (in isoform 11)"
FT                   /id="VSP_060348"
FT   VAR_SEQ         1722..1813
FT                   /note="NIDRPKGLAFTDVDVDSIKIAWESPQGQVSRYRVTYSSPEDGIHELFPAPDG
FT                   EEDTAELQGLRPGSEYTVSVVALHDDMESQPLIGTQSTAI -> TI (in isoform
FT                   8, isoform 9, isoform 10, isoform 12, isoform 13 and
FT                   isoform 14)"
FT                   /id="VSP_060349"
FT   VAR_SEQ         2081..2284
FT                   /note="KTDELPQLVTLPHPNLHGPEILDVPSTVQKTPFVTHPGYDTGNGIQLPGTSG
FT                   QQPSVGQQMIFEEHGFRRTTPPTTATPIRHRPRPYPPNVGEEIQIGHIPREDVDYHLYP
FT                   HGPGLNPNASTGQEALSQTTISWAPFQDTSEYIISCHPVGTDEEPLQFRVPGTSTSATL
FT                   TGLTRGATYNVIVEALKDQQRHKVREEVVTVGNS -> KT (in isoform 6)"
FT                   /id="VSP_060350"
FT   VAR_SEQ         2081..2201
FT                   /note="KTDELPQLVTLPHPNLHGPEILDVPSTVQKTPFVTHPGYDTGNGIQLPGTSG
FT                   QQPSVGQQMIFEEHGFRRTTPPTTATPIRHRPRPYPPNVGEEIQIGHIPREDVDYHLYP
FT                   HGPGLNPNAS -> K (in isoform 4, isoform 5, isoform 10 and
FT                   isoform 13)"
FT                   /id="VSP_060351"
FT   VAR_SEQ         2081..2106
FT                   /note="KTDELPQLVTLPHPNLHGPEILDVPS -> K (in isoform 9,
FT                   isoform 12 and isoform 17)"
FT                   /id="VSP_060352"
FT   VAR_SEQ         2173..2203
FT                   /note="Missing (in isoform 3, isoform 7, isoform 9, isoform
FT                   12, isoform 14 and isoform 17)"
FT                   /id="VSP_060353"
FT   VAR_SEQ         2239..2242
FT                   /note="FRVP -> STKA (in isoform 4)"
FT                   /id="VSP_060354"
FT   VAR_SEQ         2243..2477
FT                   /note="Missing (in isoform 4)"
FT                   /id="VSP_060355"
FT   VAR_SEQ         2285..2339
FT                   /note="Missing (in isoform 5)"
FT                   /id="VSP_060356"
FT   VARIANT         15
FT                   /note="Q -> L (in dbSNP:rs1250259)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:17974005, ECO:0000269|PubMed:18268355,
FT                   ECO:0000269|PubMed:3031656, ECO:0000269|Ref.4"
FT                   /id="VAR_043917"
FT   VARIANT         87
FT                   /note="C -> F (in SMDCF; the mutant is not secreted;
FT                   dbSNP:rs1553669703)"
FT                   /evidence="ECO:0000269|PubMed:29100092"
FT                   /id="VAR_080523"
FT   VARIANT         123
FT                   /note="C -> R (in SMDCF; dbSNP:rs1553667072)"
FT                   /evidence="ECO:0000269|PubMed:29100092"
FT                   /id="VAR_080524"
FT   VARIANT         225
FT                   /note="C -> W (in SMDCF; dbSNP:rs1181638652)"
FT                   /evidence="ECO:0000269|PubMed:29100092"
FT                   /id="VAR_080525"
FT   VARIANT         240
FT                   /note="Y -> D (in SMDCF; the mutant is not secreted;
FT                   dbSNP:rs1553659131)"
FT                   /evidence="ECO:0000269|PubMed:29100092"
FT                   /id="VAR_080526"
FT   VARIANT         260
FT                   /note="C -> G (in SMDCF; the mutant is not secreted;
FT                   dbSNP:rs1553658926)"
FT                   /evidence="ECO:0000269|PubMed:29100092"
FT                   /id="VAR_080527"
FT   VARIANT         809
FT                   /note="Missing (in SMDCF; uncertain significance;
FT                   dbSNP:rs1553636502)"
FT                   /evidence="ECO:0000269|PubMed:29100092"
FT                   /id="VAR_080528"
FT   VARIANT         817
FT                   /note="T -> P (in dbSNP:rs2577301)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:16106752, ECO:0000269|PubMed:17614963,
FT                   ECO:0000269|PubMed:17974005, ECO:0000269|PubMed:2992939,
FT                   ECO:0000269|Ref.4"
FT                   /id="VAR_059529"
FT   VARIANT         940
FT                   /note="D -> N (in a breast cancer sample; somatic mutation;
FT                   dbSNP:rs752106647)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036018"
FT   VARIANT         973
FT                   /note="Y -> C (in GFND2; dbSNP:rs137854488)"
FT                   /evidence="ECO:0000269|PubMed:18268355"
FT                   /id="VAR_043918"
FT   VARIANT         1120
FT                   /note="R -> P (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036019"
FT   VARIANT         1558
FT                   /note="S -> R (in dbSNP:rs11687611)"
FT                   /id="VAR_056576"
FT   VARIANT         1925
FT                   /note="W -> R (in GFND2; reduced binding to heparin,
FT                   endothelial cells and podocytes; impaired capability to
FT                   induce stress-fiber formation; dbSNP:rs137854486)"
FT                   /evidence="ECO:0000269|PubMed:18268355"
FT                   /id="VAR_043919"
FT   VARIANT         1974
FT                   /note="L -> R (in GFND2; reduced binding to heparin,
FT                   endothelial cells and podocytes; impaired capability to
FT                   induce stress-fiber formation; dbSNP:rs137854487)"
FT                   /evidence="ECO:0000269|PubMed:18268355"
FT                   /id="VAR_043920"
FT   VARIANT         2051
FT                   /note="I -> V (in dbSNP:rs1250209)"
FT                   /evidence="ECO:0000269|PubMed:18268355"
FT                   /id="VAR_043921"
FT   VARIANT         2212
FT                   /note="I -> V (in dbSNP:rs17449032)"
FT                   /id="VAR_056577"
FT   VARIANT         2261
FT                   /note="V -> I (in dbSNP:rs1250209)"
FT                   /evidence="ECO:0000269|PubMed:12127832,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:16106752,
FT                   ECO:0000269|PubMed:17974005, ECO:0000269|PubMed:2012601,
FT                   ECO:0000269|PubMed:2992573, ECO:0000269|PubMed:2992939,
FT                   ECO:0000269|PubMed:4019516, ECO:0000269|PubMed:6462919,
FT                   ECO:0000269|Ref.4, ECO:0007744|PubMed:21269460"
FT                   /id="VAR_061486"
FT   VARIANT         2471
FT                   /note="D -> N (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs1373375768)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036020"
FT   MUTAGEN         641
FT                   /note="Y->A: Severely compromised ability to form
FT                   fibronectin aggregates; when associated with A-681 and
FT                   A-683."
FT                   /evidence="ECO:0000269|PubMed:12946358"
FT   MUTAGEN         642
FT                   /note="I->A: Little effect on ability to form fibronectin
FT                   aggregates; when associated with A-682; A-684 and A-692."
FT                   /evidence="ECO:0000269|PubMed:12946358"
FT   MUTAGEN         663
FT                   /note="L->A: No effect on secondary structure nor on
FT                   fibronectin binding nor on activation of p38 K but
FT                   abolishes polymerization activity; when associated with
FT                   A-666."
FT                   /evidence="ECO:0000269|PubMed:12946358,
FT                   ECO:0000269|PubMed:19379667"
FT   MUTAGEN         666
FT                   /note="Y->A: No effect on secondary structure nor on
FT                   fibronectin binding nor on activation of p38 kinase but
FT                   abolishes polymerization activity; when associated with
FT                   A-663."
FT                   /evidence="ECO:0000269|PubMed:12946358,
FT                   ECO:0000269|PubMed:19379667"
FT   MUTAGEN         681
FT                   /note="L->A: Severely compromised ability to form
FT                   fibronectin aggregates; when associated with A-641 and
FT                   A-683."
FT                   /evidence="ECO:0000269|PubMed:12946358"
FT   MUTAGEN         682
FT                   /note="I->A: Little effect on ability to form fibronectin
FT                   aggregates; when associated with A-642; A-684 and A-692."
FT                   /evidence="ECO:0000269|PubMed:12946358"
FT   MUTAGEN         683
FT                   /note="S->A: Severely compromised ability to form
FT                   fibronectin aggregates; when associated with A-641 and
FT                   A-681."
FT                   /evidence="ECO:0000269|PubMed:12946358"
FT   MUTAGEN         684
FT                   /note="I->A: Little effect on ability to form fibronectin
FT                   aggregates; when associated with A-642; A-682 and A-692."
FT                   /evidence="ECO:0000269|PubMed:12946358"
FT   MUTAGEN         691
FT                   /note="E->A: Slightly enhanced ability to form fibronectin
FT                   aggregates; when associated with A-694 and A-696."
FT                   /evidence="ECO:0000269|PubMed:12946358"
FT   MUTAGEN         692
FT                   /note="V->A: Little effect on ability to form fibronectin
FT                   aggregates; when associated with A-642; A-682 and A-684."
FT                   /evidence="ECO:0000269|PubMed:12946358"
FT   MUTAGEN         694
FT                   /note="R->A: Slightly enhanced ability to form fibronectin
FT                   aggregates; when associated with A-691 and A-696."
FT                   /evidence="ECO:0000269|PubMed:12946358"
FT   MUTAGEN         695
FT                   /note="F->A: Loss of ability to form fibronectin
FT                   aggregates; when associated with A-697."
FT                   /evidence="ECO:0000269|PubMed:12946358"
FT   MUTAGEN         696
FT                   /note="D->A: Slightly enhanced ability to form fibronectin
FT                   aggregates; when associated with A-691 and A-694."
FT                   /evidence="ECO:0000269|PubMed:12946358"
FT   MUTAGEN         697
FT                   /note="F->A: Loss of ability to form fibronectin
FT                   aggregates; when associated with A-695."
FT                   /evidence="ECO:0000269|PubMed:12946358"
FT   CONFLICT        32
FT                   /note="Q -> R (in Ref. 5; CAH18171)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        48
FT                   /note="S -> C (in Ref. 12; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        52
FT                   /note="C -> S (in Ref. 12; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        69
FT                   /note="Y -> N (in Ref. 5; CAH18172)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        73
FT                   /note="A -> V (in Ref. 11; CAA26536)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        126
FT                   /note="I -> V (in Ref. 5; CAH18136)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        199
FT                   /note="E -> G (in Ref. 5; CAD91166)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        247
FT                   /note="S -> R (in Ref. 1; CAD59389 and 2; CAH60958)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        260
FT                   /note="C -> R (in Ref. 5; CAH18172)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        289
FT                   /note="V -> A (in Ref. 5; CAE45847)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        355
FT                   /note="S -> L (in Ref. 11; CAA26536 and 13; AAD00015)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        357
FT                   /note="G -> E (in Ref. 5; CAD97984)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        375
FT                   /note="T -> A (in Ref. 5; CAH18136)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        411
FT                   /note="R -> Q (in Ref. 11; CAA26536 and 13; AAD00015)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        518
FT                   /note="C -> R (in Ref. 5; CAD97791)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        552
FT                   /note="R -> K (in Ref. 5; CAD97965/CAD97964)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        580
FT                   /note="V -> A (in Ref. 5; CAH18172)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        678
FT                   /note="E -> Q (in Ref. 16; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        704..705
FT                   /note="TP -> PT (in Ref. 16; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        980
FT                   /note="V -> L (in Ref. 5; CAD97791)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1030
FT                   /note="T -> A (in Ref. 5; CAH18136)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1048
FT                   /note="V -> D (in Ref. 5; CAD97965/CAD97964)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1134
FT                   /note="D -> G (in Ref. 5; CAH18136)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1137
FT                   /note="S -> N (in Ref. 5; CAD97965/CAD97964)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1152
FT                   /note="T -> I (in Ref. 5; CAH18136)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1222
FT                   /note="E -> G (in Ref. 5; CAD97791)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1226
FT                   /note="H -> Q (in Ref. 5; CAE45932)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1646
FT                   /note="D -> G (in Ref. 5; CAE45714)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1692
FT                   /note="G -> S (in Ref. 5; CAD97965/CAD97964)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1713
FT                   /note="Q -> E (in Ref. 27; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1806..1812
FT                   /note="IGTQSTA -> VQTAVTT (in Ref. 29; AAA52463)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1817
FT                   /note="T -> A (in Ref. 5; CAE45847)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1846
FT                   /note="R -> W (in Ref. 5; CAH18136)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1859
FT                   /note="I -> V (in Ref. 19; CAB52436)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1874
FT                   /note="M -> T (in Ref. 5; CAE45932)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2018
FT                   /note="R -> C (in Ref. 13; AAD00014)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2025
FT                   /note="I -> V (in Ref. 5; CAH18172)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2083
FT                   /note="D -> G (in Ref. 5; CAD97965/CAD97964)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2114
FT                   /note="V -> A (in Ref. 5; CAD97965/CAD97964)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2118
FT                   /note="G -> R (in Ref. 5; CAD97965/CAD97964)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2342
FT                   /note="C -> R (in Ref. 5; CAH18172)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2403
FT                   /note="Y -> N (in Ref. 5; CAD97965/CAD97964)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2432
FT                   /note="S -> T (in Ref. 5;
FT                   CAE45714/CAH18171/CAH18172/CAE45958)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2458
FT                   /note="C -> Y (in Ref. 5; CAE45932)"
FT                   /evidence="ECO:0000305"
FT   STRAND          52..54
FT                   /evidence="ECO:0007829|PDB:1QGB"
FT   STRAND          57..59
FT                   /evidence="ECO:0007829|PDB:1QGB"
FT   STRAND          64..69
FT                   /evidence="ECO:0007829|PDB:1O9A"
FT   STRAND          72..78
FT                   /evidence="ECO:0007829|PDB:1O9A"
FT   TURN            81..83
FT                   /evidence="ECO:0007829|PDB:1QGB"
FT   STRAND          85..89
FT                   /evidence="ECO:0007829|PDB:1O9A"
FT   STRAND          96..98
FT                   /evidence="ECO:0007829|PDB:2CG7"
FT   TURN            100..102
FT                   /evidence="ECO:0007829|PDB:2CG7"
FT   STRAND          105..107
FT                   /evidence="ECO:0007829|PDB:2CG7"
FT   STRAND          111..116
FT                   /evidence="ECO:0007829|PDB:2CG7"
FT   STRAND          119..127
FT                   /evidence="ECO:0007829|PDB:2CG7"
FT   TURN            128..131
FT                   /evidence="ECO:0007829|PDB:2CG7"
FT   STRAND          132..136
FT                   /evidence="ECO:0007829|PDB:2CG7"
FT   STRAND          140..143
FT                   /evidence="ECO:0007829|PDB:2CG7"
FT   STRAND          146..149
FT                   /evidence="ECO:0007829|PDB:2CG7"
FT   STRAND          153..157
FT                   /evidence="ECO:0007829|PDB:2CG7"
FT   STRAND          161..171
FT                   /evidence="ECO:0007829|PDB:2CG7"
FT   TURN            172..175
FT                   /evidence="ECO:0007829|PDB:2CG7"
FT   STRAND          176..181
FT                   /evidence="ECO:0007829|PDB:2CG7"
FT   STRAND          185..188
FT                   /evidence="ECO:0007829|PDB:2RKY"
FT   TURN            189..192
FT                   /evidence="ECO:0007829|PDB:2RKY"
FT   STRAND          193..196
FT                   /evidence="ECO:0007829|PDB:2RKY"
FT   STRAND          200..205
FT                   /evidence="ECO:0007829|PDB:2RKY"
FT   TURN            206..208
FT                   /evidence="ECO:0007829|PDB:2RKY"
FT   STRAND          209..217
FT                   /evidence="ECO:0007829|PDB:2RKY"
FT   TURN            218..221
FT                   /evidence="ECO:0007829|PDB:2RKY"
FT   STRAND          222..226
FT                   /evidence="ECO:0007829|PDB:2RKY"
FT   STRAND          230..233
FT                   /evidence="ECO:0007829|PDB:2RKY"
FT   TURN            234..237
FT                   /evidence="ECO:0007829|PDB:2RKY"
FT   STRAND          238..241
FT                   /evidence="ECO:0007829|PDB:2RKY"
FT   STRAND          245..249
FT                   /evidence="ECO:0007829|PDB:2RKY"
FT   STRAND          251..253
FT                   /evidence="ECO:0007829|PDB:2RKY"
FT   STRAND          255..262
FT                   /evidence="ECO:0007829|PDB:2RKY"
FT   TURN            263..266
FT                   /evidence="ECO:0007829|PDB:2RKY"
FT   STRAND          267..271
FT                   /evidence="ECO:0007829|PDB:2RKY"
FT   STRAND          302..304
FT                   /evidence="ECO:0007829|PDB:3M7P"
FT   STRAND          307..309
FT                   /evidence="ECO:0007829|PDB:3M7P"
FT   TURN            311..313
FT                   /evidence="ECO:0007829|PDB:1E88"
FT   STRAND          315..317
FT                   /evidence="ECO:0007829|PDB:3M7P"
FT   STRAND          321..326
FT                   /evidence="ECO:0007829|PDB:3M7P"
FT   STRAND          329..336
FT                   /evidence="ECO:0007829|PDB:3M7P"
FT   STRAND          339..344
FT                   /evidence="ECO:0007829|PDB:3M7P"
FT   TURN            353..356
FT                   /evidence="ECO:0007829|PDB:3M7P"
FT   STRAND          360..366
FT                   /evidence="ECO:0007829|PDB:3M7P"
FT   STRAND          369..373
FT                   /evidence="ECO:0007829|PDB:3M7P"
FT   STRAND          381..383
FT                   /evidence="ECO:0007829|PDB:1E88"
FT   STRAND          385..391
FT                   /evidence="ECO:0007829|PDB:3M7P"
FT   HELIX           392..395
FT                   /evidence="ECO:0007829|PDB:3M7P"
FT   STRAND          398..401
FT                   /evidence="ECO:0007829|PDB:3M7P"
FT   HELIX           403..405
FT                   /evidence="ECO:0007829|PDB:1E8B"
FT   TURN            413..417
FT                   /evidence="ECO:0007829|PDB:3M7P"
FT   STRAND          422..426
FT                   /evidence="ECO:0007829|PDB:3M7P"
FT   STRAND          429..433
FT                   /evidence="ECO:0007829|PDB:3M7P"
FT   STRAND          440..442
FT                   /evidence="ECO:0007829|PDB:2FN2"
FT   STRAND          445..451
FT                   /evidence="ECO:0007829|PDB:3M7P"
FT   HELIX           452..455
FT                   /evidence="ECO:0007829|PDB:3M7P"
FT   STRAND          458..460
FT                   /evidence="ECO:0007829|PDB:3M7P"
FT   HELIX           465..467
FT                   /evidence="ECO:0007829|PDB:3MQL"
FT   STRAND          469..471
FT                   /evidence="ECO:0007829|PDB:3M7P"
FT   STRAND          477..479
FT                   /evidence="ECO:0007829|PDB:3M7P"
FT   STRAND          483..485
FT                   /evidence="ECO:0007829|PDB:3M7P"
FT   STRAND          490..492
FT                   /evidence="ECO:0007829|PDB:3M7P"
FT   STRAND          495..500
FT                   /evidence="ECO:0007829|PDB:3M7P"
FT   TURN            501..504
FT                   /evidence="ECO:0007829|PDB:3M7P"
FT   STRAND          505..513
FT                   /evidence="ECO:0007829|PDB:3M7P"
FT   STRAND          517..520
FT                   /evidence="ECO:0007829|PDB:3EJH"
FT   STRAND          523..526
FT                   /evidence="ECO:0007829|PDB:3EJH"
FT   STRAND          529..534
FT                   /evidence="ECO:0007829|PDB:3EJH"
FT   STRAND          540..547
FT                   /evidence="ECO:0007829|PDB:3EJH"
FT   TURN            548..551
FT                   /evidence="ECO:0007829|PDB:3EJH"
FT   STRAND          552..557
FT                   /evidence="ECO:0007829|PDB:3EJH"
FT   STRAND          559..562
FT                   /evidence="ECO:0007829|PDB:3EJH"
FT   TURN            564..566
FT                   /evidence="ECO:0007829|PDB:3EJH"
FT   STRAND          569..571
FT                   /evidence="ECO:0007829|PDB:3EJH"
FT   STRAND          575..578
FT                   /evidence="ECO:0007829|PDB:3EJH"
FT   STRAND          585..591
FT                   /evidence="ECO:0007829|PDB:3EJH"
FT   TURN            592..595
FT                   /evidence="ECO:0007829|PDB:3EJH"
FT   STRAND          596..601
FT                   /evidence="ECO:0007829|PDB:3EJH"
FT   STRAND          613..615
FT                   /evidence="ECO:0007829|PDB:1OWW"
FT   STRAND          626..631
FT                   /evidence="ECO:0007829|PDB:1OWW"
FT   STRAND          634..636
FT                   /evidence="ECO:0007829|PDB:1OWW"
FT   STRAND          638..647
FT                   /evidence="ECO:0007829|PDB:1OWW"
FT   TURN            648..651
FT                   /evidence="ECO:0007829|PDB:1Q38"
FT   STRAND          655..659
FT                   /evidence="ECO:0007829|PDB:1OWW"
FT   STRAND          661..664
FT                   /evidence="ECO:0007829|PDB:1Q38"
FT   STRAND          665..668
FT                   /evidence="ECO:0007829|PDB:1OWW"
FT   STRAND          673..688
FT                   /evidence="ECO:0007829|PDB:1OWW"
FT   STRAND          690..699
FT                   /evidence="ECO:0007829|PDB:1OWW"
FT   HELIX           732..734
FT                   /evidence="ECO:0007829|PDB:2H41"
FT   STRAND          736..739
FT                   /evidence="ECO:0007829|PDB:2H41"
FT   STRAND          747..756
FT                   /evidence="ECO:0007829|PDB:2H41"
FT   TURN            757..759
FT                   /evidence="ECO:0007829|PDB:2H41"
FT   STRAND          764..769
FT                   /evidence="ECO:0007829|PDB:2H41"
FT   STRAND          774..777
FT                   /evidence="ECO:0007829|PDB:2H41"
FT   STRAND          785..794
FT                   /evidence="ECO:0007829|PDB:2H41"
FT   STRAND          799..808
FT                   /evidence="ECO:0007829|PDB:2H41"
FT   STRAND          818..822
FT                   /evidence="ECO:0007829|PDB:2N1K"
FT   STRAND          824..830
FT                   /evidence="ECO:0007829|PDB:2N1K"
FT   STRAND          839..847
FT                   /evidence="ECO:0007829|PDB:2N1K"
FT   STRAND          854..859
FT                   /evidence="ECO:0007829|PDB:2N1K"
FT   STRAND          864..869
FT                   /evidence="ECO:0007829|PDB:2N1K"
FT   STRAND          875..883
FT                   /evidence="ECO:0007829|PDB:2N1K"
FT   STRAND          892..897
FT                   /evidence="ECO:0007829|PDB:2N1K"
FT   STRAND          911..918
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          923..928
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          936..945
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          947..949
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          951..958
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          960..964
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          972..981
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          989..994
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          1001..1007
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          1009..1011
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          1013..1018
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          1025..1033
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          1040..1044
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          1049..1053
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          1061..1070
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          1078..1083
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          1094..1098
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          1103..1107
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          1113..1121
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          1129..1140
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          1148..1157
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          1166..1171
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          1178..1184
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   TURN            1186..1188
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          1191..1196
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          1199..1202
FT                   /evidence="ECO:0007829|PDB:7NWL"
FT   STRAND          1205..1212
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   TURN            1213..1215
FT                   /evidence="ECO:0007829|PDB:1FNF"
FT   STRAND          1221..1225
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          1230..1234
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          1239..1241
FT                   /evidence="ECO:0007829|PDB:5N47"
FT   STRAND          1243..1251
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          1259..1263
FT                   /evidence="ECO:0007829|PDB:6MFA"
FT   STRAND          1274..1277
FT                   /evidence="ECO:0007829|PDB:5N48"
FT   STRAND          1280..1286
FT                   /evidence="ECO:0007829|PDB:5N48"
FT   STRAND          1291..1294
FT                   /evidence="ECO:0007829|PDB:2GEE"
FT   STRAND          1295..1304
FT                   /evidence="ECO:0007829|PDB:5N48"
FT   TURN            1305..1308
FT                   /evidence="ECO:0007829|PDB:8PEQ"
FT   STRAND          1311..1317
FT                   /evidence="ECO:0007829|PDB:5N48"
FT   STRAND          1322..1327
FT                   /evidence="ECO:0007829|PDB:5N48"
FT   STRAND          1333..1342
FT                   /evidence="ECO:0007829|PDB:5N48"
FT   STRAND          1350..1355
FT                   /evidence="ECO:0007829|PDB:5N48"
FT   STRAND          1362..1368
FT                   /evidence="ECO:0007829|PDB:1FNF"
FT   STRAND          1374..1379
FT                   /evidence="ECO:0007829|PDB:1FNF"
FT   STRAND          1387..1395
FT                   /evidence="ECO:0007829|PDB:1FNF"
FT   HELIX           1396..1398
FT                   /evidence="ECO:0007829|PDB:3T1W"
FT   HELIX           1399..1401
FT                   /evidence="ECO:0007829|PDB:2GEE"
FT   STRAND          1403..1407
FT                   /evidence="ECO:0007829|PDB:1FNF"
FT   STRAND          1413..1416
FT                   /evidence="ECO:0007829|PDB:1FNF"
FT   STRAND          1424..1433
FT                   /evidence="ECO:0007829|PDB:1FNF"
FT   STRAND          1441..1446
FT                   /evidence="ECO:0007829|PDB:1FNF"
FT   STRAND          1453..1459
FT                   /evidence="ECO:0007829|PDB:4LXO"
FT   STRAND          1465..1470
FT                   /evidence="ECO:0007829|PDB:4LXO"
FT   STRAND          1477..1485
FT                   /evidence="ECO:0007829|PDB:4LXO"
FT   STRAND          1493..1497
FT                   /evidence="ECO:0007829|PDB:4LXO"
FT   STRAND          1503..1506
FT                   /evidence="ECO:0007829|PDB:4LXO"
FT   STRAND          1514..1523
FT                   /evidence="ECO:0007829|PDB:4LXO"
FT   STRAND          1531..1536
FT                   /evidence="ECO:0007829|PDB:4LXO"
FT   STRAND          1543..1551
FT                   /evidence="ECO:0007829|PDB:4LXO"
FT   STRAND          1554..1560
FT                   /evidence="ECO:0007829|PDB:4LXO"
FT   STRAND          1567..1575
FT                   /evidence="ECO:0007829|PDB:4LXO"
FT   STRAND          1578..1580
FT                   /evidence="ECO:0007829|PDB:5DC9"
FT   STRAND          1583..1588
FT                   /evidence="ECO:0007829|PDB:4LXO"
FT   STRAND          1593..1596
FT                   /evidence="ECO:0007829|PDB:4LXO"
FT   STRAND          1604..1613
FT                   /evidence="ECO:0007829|PDB:4LXO"
FT   STRAND          1616..1618
FT                   /evidence="ECO:0007829|PDB:4LXO"
FT   STRAND          1625..1630
FT                   /evidence="ECO:0007829|PDB:4LXO"
FT   STRAND          1637..1644
FT                   /evidence="ECO:0007829|PDB:6XAX"
FT   STRAND          1649..1654
FT                   /evidence="ECO:0007829|PDB:6XAX"
FT   STRAND          1661..1674
FT                   /evidence="ECO:0007829|PDB:6XAX"
FT   STRAND          1677..1681
FT                   /evidence="ECO:0007829|PDB:6XAX"
FT   STRAND          1687..1690
FT                   /evidence="ECO:0007829|PDB:6XAX"
FT   STRAND          1698..1706
FT                   /evidence="ECO:0007829|PDB:6XAX"
FT   STRAND          1715..1720
FT                   /evidence="ECO:0007829|PDB:6XAX"
FT   STRAND          1727..1733
FT                   /evidence="ECO:0007829|PDB:6XAX"
FT   STRAND          1739..1744
FT                   /evidence="ECO:0007829|PDB:6XAX"
FT   STRAND          1751..1759
FT                   /evidence="ECO:0007829|PDB:6XAX"
FT   TURN            1760..1762
FT                   /evidence="ECO:0007829|PDB:6XAX"
FT   STRAND          1763..1766
FT                   /evidence="ECO:0007829|PDB:6XAX"
FT   STRAND          1772..1774
FT                   /evidence="ECO:0007829|PDB:6XAX"
FT   STRAND          1777..1780
FT                   /evidence="ECO:0007829|PDB:6XAX"
FT   STRAND          1788..1797
FT                   /evidence="ECO:0007829|PDB:6XAX"
FT   STRAND          1805..1810
FT                   /evidence="ECO:0007829|PDB:6XAX"
FT   STRAND          1817..1824
FT                   /evidence="ECO:0007829|PDB:3R8Q"
FT   STRAND          1829..1834
FT                   /evidence="ECO:0007829|PDB:3R8Q"
FT   STRAND          1842..1854
FT                   /evidence="ECO:0007829|PDB:3R8Q"
FT   STRAND          1857..1861
FT                   /evidence="ECO:0007829|PDB:3R8Q"
FT   STRAND          1867..1870
FT                   /evidence="ECO:0007829|PDB:3R8Q"
FT   STRAND          1878..1887
FT                   /evidence="ECO:0007829|PDB:3R8Q"
FT   STRAND          1895..1900
FT                   /evidence="ECO:0007829|PDB:3R8Q"
FT   STRAND          1909..1916
FT                   /evidence="ECO:0007829|PDB:3R8Q"
FT   STRAND          1921..1926
FT                   /evidence="ECO:0007829|PDB:3R8Q"
FT   STRAND          1934..1944
FT                   /evidence="ECO:0007829|PDB:3R8Q"
FT   STRAND          1948..1952
FT                   /evidence="ECO:0007829|PDB:3R8Q"
FT   STRAND          1957..1961
FT                   /evidence="ECO:0007829|PDB:3R8Q"
FT   STRAND          1969..1978
FT                   /evidence="ECO:0007829|PDB:3R8Q"
FT   STRAND          1986..1991
FT                   /evidence="ECO:0007829|PDB:3R8Q"
FT   STRAND          1998..2006
FT                   /evidence="ECO:0007829|PDB:3R8Q"
FT   STRAND          2009..2015
FT                   /evidence="ECO:0007829|PDB:3R8Q"
FT   STRAND          2023..2029
FT                   /evidence="ECO:0007829|PDB:3R8Q"
FT   STRAND          2033..2037
FT                   /evidence="ECO:0007829|PDB:6HNF"
FT   STRAND          2048..2051
FT                   /evidence="ECO:0007829|PDB:3R8Q"
FT   STRAND          2059..2068
FT                   /evidence="ECO:0007829|PDB:3R8Q"
FT   STRAND          2076..2081
FT                   /evidence="ECO:0007829|PDB:3R8Q"
FT   STRAND          2206..2213
FT                   /evidence="ECO:0007829|PDB:5M0A"
FT   STRAND          2221..2232
FT                   /evidence="ECO:0007829|PDB:5M0A"
FT   STRAND          2237..2242
FT                   /evidence="ECO:0007829|PDB:5M0A"
FT   STRAND          2247..2254
FT                   /evidence="ECO:0007829|PDB:5M0A"
FT   STRAND          2257..2267
FT                   /evidence="ECO:0007829|PDB:5M0A"
FT   STRAND          2270..2280
FT                   /evidence="ECO:0007829|PDB:5M0A"
FT   STRAND          2344..2346
FT                   /evidence="ECO:0007829|PDB:2EC3"
FT   STRAND          2354..2358
FT                   /evidence="ECO:0007829|PDB:2EC3"
FT   STRAND          2360..2371
FT                   /evidence="ECO:0007829|PDB:2EC3"
FT   TURN            2372..2375
FT                   /evidence="ECO:0007829|PDB:2EC3"
FT   STRAND          2376..2381
FT                   /evidence="ECO:0007829|PDB:2EC3"
SQ   SEQUENCE   2477 AA;  272320 MW;  6C436A7A5FEE6DEB CRC64;
     MLRGPGPGLL LLAVQCLGTA VPSTGASKSK RQAQQMVQPQ SPVAVSQSKP GCYDNGKHYQ
     INQQWERTYL GNALVCTCYG GSRGFNCESK PEAEETCFDK YTGNTYRVGD TYERPKDSMI
     WDCTCIGAGR GRISCTIANR CHEGGQSYKI GDTWRRPHET GGYMLECVCL GNGKGEWTCK
     PIAEKCFDHA AGTSYVVGET WEKPYQGWMM VDCTCLGEGS GRITCTSRNR CNDQDTRTSY
     RIGDTWSKKD NRGNLLQCIC TGNGRGEWKC ERHTSVQTTS SGSGPFTDVR AAVYQPQPHP
     QPPPYGHCVT DSGVVYSVGM QWLKTQGNKQ MLCTCLGNGV SCQETAVTQT YGGNSNGEPC
     VLPFTYNGRT FYSCTTEGRQ DGHLWCSTTS NYEQDQKYSF CTDHTVLVQT RGGNSNGALC
     HFPFLYNNHN YTDCTSEGRR DNMKWCGTTQ NYDADQKFGF CPMAAHEEIC TTNEGVMYRI
     GDQWDKQHDM GHMMRCTCVG NGRGEWTCIA YSQLRDQCIV DDITYNVNDT FHKRHEEGHM
     LNCTCFGQGR GRWKCDPVDQ CQDSETGTFY QIGDSWEKYV HGVRYQCYCY GRGIGEWHCQ
     PLQTYPSSSG PVEVFITETP SQPNSHPIQW NAPQPSHISK YILRWRPKNS VGRWKEATIP
     GHLNSYTIKG LKPGVVYEGQ LISIQQYGHQ EVTRFDFTTT STSTPVTSNT VTGETTPFSP
     LVATSESVTE ITASSFVVSW VSASDTVSGF RVEYELSEEG DEPQYLDLPS TATSVNIPDL
     LPGRKYIVNV YQISEDGEQS LILSTSQTTA PDAPPDTTVD QVDDTSIVVR WSRPQAPITG
     YRIVYSPSVE GSSTELNLPE TANSVTLSDL QPGVQYNITI YAVEENQEST PVVIQQETTG
     TPRSDTVPSP RDLQFVEVTD VKVTIMWTPP ESAVTGYRVD VIPVNLPGEH GQRLPISRNT
     FAEVTGLSPG VTYYFKVFAV SHGRESKPLT AQQTTKLDAP TNLQFVNETD STVLVRWTPP
     RAQITGYRLT VGLTRRGQPR QYNVGPSVSK YPLRNLQPAS EYTVSLVAIK GNQESPKATG
     VFTTLQPGSS IPPYNTEVTE TTIVITWTPA PRIGFKLGVR PSQGGEAPRE VTSDSGSIVV
     SGLTPGVEYV YTIQVLRDGQ ERDAPIVNKV VTPLSPPTNL HLEANPDTGV LTVSWERSTT
     PDITGYRITT TPTNGQQGNS LEEVVHADQS SCTFDNLSPG LEYNVSVYTV KDDKESVPIS
     DTIIPEVPQL TDLSFVDITD SSIGLRWTPL NSSTIIGYRI TVVAAGEGIP IFEDFVDSSV
     GYYTVTGLEP GIDYDISVIT LINGGESAPT TLTQQTAVPP PTDLRFTNIG PDTMRVTWAP
     PPSIDLTNFL VRYSPVKNEE DVAELSISPS DNAVVLTNLL PGTEYVVSVS SVYEQHESTP
     LRGRQKTGLD SPTGIDFSDI TANSFTVHWI APRATITGYR IRHHPEHFSG RPREDRVPHS
     RNSITLTNLT PGTEYVVSIV ALNGREESPL LIGQQSTVSD VPRDLEVVAA TPTSLLISWD
     APAVTVRYYR ITYGETGGNS PVQEFTVPGS KSTATISGLK PGVDYTITVY AVTGRGDSPA
     SSKPISINYR TEIDKPSQMQ VTDVQDNSIS VKWLPSSSPV TGYRVTTTPK NGPGPTKTKT
     AGPDQTEMTI EGLQPTVEYV VSVYAQNPSG ESQPLVQTAV TNIDRPKGLA FTDVDVDSIK
     IAWESPQGQV SRYRVTYSSP EDGIHELFPA PDGEEDTAEL QGLRPGSEYT VSVVALHDDM
     ESQPLIGTQS TAIPAPTDLK FTQVTPTSLS AQWTPPNVQL TGYRVRVTPK EKTGPMKEIN
     LAPDSSSVVV SGLMVATKYE VSVYALKDTL TSRPAQGVVT TLENVSPPRR ARVTDATETT
     ITISWRTKTE TITGFQVDAV PANGQTPIQR TIKPDVRSYT ITGLQPGTDY KIYLYTLNDN
     ARSSPVVIDA STAIDAPSNL RFLATTPNSL LVSWQPPRAR ITGYIIKYEK PGSPPREVVP
     RPRPGVTEAT ITGLEPGTEY TIYVIALKNN QKSEPLIGRK KTDELPQLVT LPHPNLHGPE
     ILDVPSTVQK TPFVTHPGYD TGNGIQLPGT SGQQPSVGQQ MIFEEHGFRR TTPPTTATPI
     RHRPRPYPPN VGEEIQIGHI PREDVDYHLY PHGPGLNPNA STGQEALSQT TISWAPFQDT
     SEYIISCHPV GTDEEPLQFR VPGTSTSATL TGLTRGATYN VIVEALKDQQ RHKVREEVVT
     VGNSVNEGLN QPTDDSCFDP YTVSHYAVGD EWERMSESGF KLLCQCLGFG SGHFRCDSSR
     WCHDNGVNYK IGEKWDRQGE NGQMMSCTCL GNGKGEFKCD PHEATCYDDG KTYHVGEQWQ
     KEYLGAICSC TCFGGQRGWR CDNCRRPGGE PSPEGTTGQS YNQYSQRYHQ RTNTNVNCPI
     ECFMPLDVQA DREDSRE
//
